150 Metcalfe Street, Suite 2100 Ottawa, Ontario K2P 1P1 Telephone: (613) 751-4460 Facsimile: (613) 751-4474 Email: [email protected] Website: www.genomecanada.ca Published by Genome Canada ACKNOWLEDGEMENT Extracts from this document may be reproduced for individual use without permission provided the Government of Canada source is fully acknowledged. However, reproduction in whole or in part for purposes of resale or redistribution requires prior written permission from Genome Canada. Genome Canada would like to thank the Government of Canada for its support. © Genome Canada 2009 Corporate Plan 2009–10 TABLE OF CONTENTS i

Executive Summary 1 GENOME CANADA — Corporate Plan 2009–10

Section I – About Genome Canada 4

Section II – Pursuing our Objectives: Performance for 2008–09 8

Section III – Grant Management for 2008–09 23

Section IV – Plans for 2009–10 26

Section V – Performance, Audit and Evaluation Strategy 31 32 GENOME CANADA — Corporate Plan 2009–10 SECTION V izing anationalsystemforcapturingperformanceinformationfromacrossallprojectsinconsolidatedmanner. In fiscal year 2009–10, Genome Canada will concentrate on completing the process for assessing final project reports, and on final Directors inMarch2009. of Board the to submission for planned are undertakings significant two these on reports Final undertaken. were Canada Industry with agreement funding the in PAESand the in both for called were that evaluation the and audit performance the of completion ensuring to related activities 2008–09, (www.genomecanada.ca).In website Canada’s Genome on full in viewed be can PAESThe FINANCIAL AUDITS ANDANNUAL REPORTS 2002-03 (Quebec City) Genome Canada Retreat –

Performance, AuditandEvaluationStrategy 2003-04 EVALUATION (RMAF) 2004-05 (Winnipeg) Genome Canada Retreat

C 2005-06 OMPLIANCE A UDIT 2006-07 (Ottawa) Genome Canada Retreat AUDIT AND STRATEGY EVALUATION

2007-08 2008-09 AUDIT PERFORMANCE

EVALUATION - EXECUTIVE SUMMARY the final reports will be developed in 2009–10 as part as 2009–10 in developed be will reports final the Aquaculture, were received. The process for the review of Genome España in the areas of Human Health, Plants and with competition international bilateral first Canada’s Genome and Health, Human in ProteomicsResearch and Genomics Applied competition, strategic first Canada’s Genome of reports final the 2008–09, year fiscal In practices indeliveringhighqualitytechnologyservices. and methods best as well as technologies, in advances of details share and meet to platforms other of leaders and platforms, Canada-funded Genome six the of leaders the which took place in January 2009 was an opportunity for meeting Leaders Platform Technology and Science The community. scientific Canadian entire the to available technologies of menu the update and widen will results These 2010. in results produce will Competition opment Technologythe of aegis the under funded projects Devel research innovative thirteen The researchers. proteomics and genomics Canadian for available is technology edge cutting- that ensuring to committed is Canada Genome funding support. merit which areas as PositionPaperProcess the of cycle second the in identified agriculture-animals—were and health themes—child research strategic more two 2008, of fall the In support. funding merit which areas as cycle Paper Position first the in recommended been had themes research two These bioproducts. and plants agriculture– of themes research strategic the address to competition a launched Canada Genome 2008–09, In role in the overall strategic activities of Genome Canada. pivotal a play to continued Canadians) to importance socio-economic of and interest of areas recognized funding to targeted strategic research themes in nationally allocating for approach (an Process Paper Position The national and global scientific and socio-economic impact,andreceiptbyGenomeCanadaofnewfundingsupport. national andglobalscientificsocio-economic outcomes of international peer reviews, assessments of scientific merit and relevance, assessments of the potential for any new large-scale research activities in 2009–10 will be contingent upon a number of factors, including the successful the fiscal framework of funding allocated to Genome Canada for the achievement of its five objectives, the initiation of within fall activities proposed the While 2009–10. year fiscal for results expected and activities planned the outlines Genome Canada’s Corporate Plan 2009–10 summarizes the activities and results achieved in fiscal year 2008–09 and -

and the economy. Also in 2008–09, Genome Canada's Genome 2008–09, in Also economy. the and scientific advances and their potential impact on society latest the hear to industry and media the government, academia, in policy-makers and decision- researchers, for platform exciting an Society—offered on Science of Impact The Vision: conference—2020 international third Canada’s Genome industry). aquaculture the to related projects research genomics large-scale of collaboration on (focused partnership Canada–Chile the and health), human to related projects research genomics large-scale of collaboration on (focused partnership Canada–Italy the Consortium, Genome Cancer International the Life, of Barcode International the Consortium, Regulome International the as such opportunities future in involvement as well as Forum, organization of the second annual International Funders’ the included initiatives Other scientists. Canadian and Canada of status international the enhances and Consortium—strengthens Cell Stem Cancer the and Genomics, the International Knockout Mouse Consortium, in PopulationProjectPublic the Consortium, Genomics Structural initiatives—the consortium international Genome Canada’s ongoing support and interest in several research projects, workshops, consortia and partnerships. international select in leadership of assumption and targeted in 2008–09. The strategy involved engagement specifically was research proteomics and genomics of arena international the in presence Canada’s Genome these projects. offered, including the potential applications arising from benefits socio-economic the also but objectives, project the to relative accomplishments the determine only not will, projects these of assessment comprehensive A activities. Strategy Evaluation and Audit Performance, Canada’s Genome of implementation on-going the of GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 1 2 GENOME CANADA — Corporate Plan 2009–10 EXECUTIVE SUMMARY Changing Landscape; recruitment of a Chief GE Chief a of recruitment Landscape; Changing of an international GE international an of organization initiatives: following the with framework research) genomics with associated issues social and legal refine its national GE and advance to continued Canada Genome 2008–09, In the meetingofeachproject’sobjectives. monitoring is in place to ensure continued progress towards of these interim reviews were successfully resolved. Ongoing each for committees review international the by identified issues remaining all 2008–09, In platforms. Technology and Science Canada-funded Genome six of review interim of 33 projects funded through Competition III, as well as an significant by co-funding undertaking of an interim review management, selection and support of excellent science, and application of rigorous principles and standards for project its demonstrated Canada Genome 2007–08, During to anend. came ligands protein to related project the in involvement proteomics research collaborations and consortiums. It consortiums. and collaborations research proteomics and genomics international important in participation continued with leadership international its strengthen will Canada Genome importance.international and national of research scientific for opportunities rich the on capitalize and research proteomics and genomics of edge cutting the at presence its sustain to desire its reflect 2009–10 for initiatives ongoing and proposed Canada’s Genome research totheCanadianpublicandkeystakeholders. proteomics and genomics of successes and rewards risks, the communicated Canada Genome ways many the among were exhibition travelling Genome In GEEE! the support to Nature of Museum Canadian the with partnership and programs, education youth and conferences science key of Press conferences, a new web site, press releases, sponsorship international leadershipintheareaofGE and national assuming for strategy a of development and 3 LS (ethical, environmental, economic, 3 LS symposium—Navigating the symposium—Navigating LS 3 LS. 3 LS Officer,LS that GenomeCanadahascometorepresent. proteomics and genomics in creativity and innovation the from benefit to continue Canadians and Canada the research momentum it has created and ensure that funding will enable Genome Canada to keep pace with edge in these fields. Additional and appropriate federal knowl- and development discovery, for force national a become has Canada Genome Canada, in research proteomics and genomics for resource information and funding primary the as establishment its Since Canada tofulfilitsfiveobjectives. Genome for corrections” “course necessary any make to order in assessment evaluation the review will and, effectiveness; economy,cost of and terms efficiency in Canada’s operations and programs are “best-in-class” Genome ensure to order in suggestions and practices best for audit performance five-year the of results the mine will It research. genomics in developments new changing rapidly technology,and platform genomics, polar release, data to respect with knowledge latest the gain to researchers genomics international and will facilitate workshops and conferences for Canadian Each oftheelementsandtheirunderlyingcomponentsisdisplayedinfigurebelow. SECTION V • EvaluationFramework • AuditFramework • Performance MonitoringandMeasurementFramework The threekeyelementsare: The PAES comprisesthreekeyelementsandtwosupportingelements, eachofwhichareintegraltothestrategy. these functionsismaintained.ImplementationoftheStrategybeganin2008-09. specific requirements of the latest funding agreement Canada, with and Industry to ensure that a comprehensive and integrated approach to and evaluation. In 2007–08, the Board of Genome Canada approved a new Performance, Audit and Evaluation Strategy (PAES) to respond to Genome Canada has a wide array of policies, systems and processes that have been developed over time to address issues of performance, audit ** The term“Project” meansbothResearchProjects andScienceTechnology Platforms. • Final • Performance • Interim • Project • Project PERFORMANCE MONITORING Project • RiskManagementFrameworkOperationsand •GovernanceRegime

Selection Review Monitoring – •CorporatePlanAnnualReportWebSiteSpecialPublications Performance, AuditandEvaluation Strategy Reports Indicators ** PERFORMANCE REPORTING RISK MANAGEMENT • Performance • Compliance • Recipient • Financial AUDITS • • The twosupportingelementsare: Audits Audits Risk Management Performance Reporting Audits Audits • Evaluations • Logic • Results-based and Accountability Framework (RMAF) EVALUATION Model every Management five years

31 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 30 GENOME CANADA — Corporate Plan 2009–10 SECTION 1V ClosingCashBalance OpeningCashBalance Excess(deficiency)of PROGRAM ANDOPERATING DISBURSEMENTS InvestmentIncome GovernmentofCanada RECEIPTS Planned Revenues Subsequent and Years Expenditures and 2009–10 RECEIPTSANDDISBURSEMENTS2009–10 PLANNED budget forfiscalyear2009–10willbepresentedtotheGenomeCanadaBoardofDirectorsapprovalinMarch2009. 2009meetings.Theoperating is basedonstatementsofcashflowaspresentedtotheBoardDirectorsatitsDecember2008andFebruary estimateofthereceipts anddisbursementsfor2009-10subsequentfiscalyears.Theestimate The followingtableprovidesapreliminary * As at February 2009 * AsatFebruary Revenue overDisbursements Total Disbursements Co-Funding Structural GenomicsConsortium Bovine GenomeSequencingProject Applied GenomicsinBioproductsandCrops Applied GenomicsInHumanHealthCompetition Competition III Competition II Competition I GenomeCentres(6) GenomeCanada Operating Expenditures Technology Development Cancer StemCellConsortium C. difficile EspanaCompetition Genome Canada-Genoma International BarcodeofLife International RegulomeConsortium Public Population Project inGenomics S&T Platforms Research Projects

– DETAILS Plansfor2009–10 (in millionsofdollars)* CUMULATIVE 720.6 673.0 to FORECAST 487.1 104.1 636.2 150.6 146.2 2008-09 2000-01 47.6 47.6 81.8 84.4 80.6 46.9 59.9 22.6 57.2 6.0 6.6 0.2 4.3 2.3 7.7 0.1

(17.7) 102.0 PLANNED 29.9 76.9 47.6 84.3 10.8 14.3 46.5 82.9 09-10 8.8 4.6 5.0 5.6 2.0 2.0 9.5 5.5 1.4 1.7

to 2010-2011 PLANNED (26.8) 149.2 2012-13 122.4 120.9 88.4 29.9 41.0 19.8 23.0 27.0 10.0 14.0 46.1 4.6 4.7 3.1 1.5

CUMULATIVE 924.2 PLANNED 652.4 927.3 to 159.4 840.0 2000-01 112.4 146.2 2012-13 207.1 80.6 66.4 93.0 59.9 55.6 87.3 32.3 15.8 * 25.0 4.0 6.0 9.9 0.2 7.7 3.1 3.1 2.1

1,028.0 1,028.0 CO-FUNDING to ESTIMATED 1,028.0 2000-01 2012-13 927.5 208.6 FROM 140.5 47.0 175.3 53.5 60.0 63.4 55.5 57.0 53.5 73.6 73.7 0.4 0.2 2.0 7.8 9.5

1,579.9 1,952.2 1,955.3 FUNDING GENOME CANADA 1,028.0 TOTAL & 159.9 212.9 840.0 CO- 207.6 286.7 154.3 415.7 133.5 119.9 112.6 85.0 69.4 93.0 87.3 15.5 71.3 19.4 0.4 4.4 4.1

100.0% 100.0% 80.9% 10.9% 8.2% 43.0% 52.6% 10.6% 14.7% 21.3% % 0.0% 0.8% 4.8% 4.4% 6.8% 5.8% 4.5% 0.2% 0.2% 3.6% 7.9% 3.7% 1.0% 6.1%

NEW ONGOING COMPLETED ONGOING DEVELOPMENT UNDER ONGOING COMPLETED OPERATING EXPENDITURES SCIENCE &TECHNOLOGY PLATFORMS STRATEGIC RESEARCHPRIORITIES Projects strategic priorities that have the potential for national and global scientific and socio-economic impact strategic prioritiesthathavethepotentialfornationalandglobalscientific andsocio-economic Research initiativesandactivitiesthatarecurrentlyunderdevelopment havebeenidentifiedbyGenomeCanadaassignificant Research initiativesandactivitiescurrentlysupportedbyGenomeCanada Status GENOME CANADAEXECUTIVESUMMARY • Polar • Genome • Genome • Education • Science • Competition • Technology • Competition • Applied • Turning DataintoKnowledgeWorkshop New GenomicsF Child HealthGenomicsCompetition Genomics Competition Aquatic &T Meeting Research inBioproductsorCrops Health Competition Genomics & Genomics Centres Canada National Technology and errestrial Animal Development in III Public Applied Workshop rontiers Competition Operations Operations Research Platform Outreach Genomics Competition in Human Leaders

• Data • • International • 3 • Protein • International • Cancer • International • Public • Structural • Aquaculture Competition Projects inHumanHealth,Plantsand Genome Canada/GenomaEspañaJoint Canada- Canada-Italy P International RegulomeConsortium(IRC) International BarcodeofLife(iBOL) International CancerGenomicsConsortium(ICGC) 4 rd th GenomeCanadaInternationalConference InternationalGenomicsConference Release Population Stem Ligand Chile Partnership Genomics International Cell Workshop Funders GE Knockout artnership Workshop 3 Consortium LS Symposium Project Consortium Forum Mouse in Genomics (CSCC) Consortium (SGC) (P

3 G) GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 3 4 GENOME CANADA — Corporate Plan 2009–10 SECTION 1– munity, as reflected in the receipt of large numbers large of receipt the in munity,reflected as has generated much interest from the research com- date to competitions five Canada’s Genome of Each and technology(S&T)platforms. 128 than innovative, large-scale research projects more and science support to $1.9B over total will investment the sectors, philanthropic and public private, the in partners from commitments funding proteomics research. When combined with estimated and genomics to $900M than more of commitment Canada. To date, Genome Canada has planned for the to importance scientific strategic of projects scale research hospitals and the public in support of large- government departments and agencies, universities, industry,together brings Canada Genome partners. international and domestic both with projects of proteomics research in regionsand across Canada and genomics the co-funding in expertise of points focal of fostering the includes technology also It and platforms. science and projects peer-reviewed research international multidisciplinary, and large-scale managing and funding of premise the on based is model business Canada’s Genome these andotherissues. on Canadians with communicating to and research, and social (GE social and with regard to ethical, environmental, economic, legal role leadership a assuming to committed is Canada Genome well, As development. technology new and fisheries forestry, environment, agriculture, health, benefit of all Canadians in key selected areas such as strategy in genomics and proteomics research for the national implementa develop and to mandateis Its research. proteomics and genomics in leader world a as Canada position to is vision Canada’s Genome to genomicsandproteomicsresearchinCanada. relating resource information fundingand primary the is It Canada. Industry agreement with funding a through formalized is government the to link Its Ontario. Ottawa, in office head its with 2000, February in created was Canada Genome government. federal the from length arm’s at corporation, not-for-profit a is Canada Genome 3 ) issues associated with genomics with associated issues LS)

About GenomeCanada • projects haveledto: Canada-funded Genome example, For community. benefits not only for Canadians, but alsosocio-economic for thehave global will that projects innovative launching in lead the taken has Canada Genome research priorities. proteomics and genomics international of strategic identification the in leadership and expertise contributing is Canada Genome collaborations, multilateral and bilateral developing to workshops and symposia international in participating funding and from ranging activities proteomics Through and arena. genomics international the in player major a as recognized is Canada Genome for regionalpublicoutreachprograms. opportunities create Centres Genome the thermore, Fur fundraising. and management development, project to approaches different applying in assist and platforms, S&T leading-edge to access facilitate Centres Genome the areas, proteomics-related and proteomics research. For researchers in all genomics- tions that support, at a regional level, genomics and organiza not-for-profit are Centres Genome These Montreal, Toronto, Saskatoon, Calgary and Vancouver. Six Canadian Genome Centres are located in Halifax, outstanding internationalresearchcollaborations. ties for Canada’s scientists to develop skills and lead opportuni- providing by potential this unleashing is research in genomics cutting-edge and proteomics. for Genome Canadapotential untapped Canada’s to speaks panels review peer international by reviewed of Letters of Intent. The number of excellent projects the development of a simple blood test to to test heart condition; ahereditary identify blood simple a of development the - - 5 4 • of its National GE National its of In 2009–10, Genome Canada will commence implementation Leadership totheNextLevel” also continue to nurture existing relationships to ensure maximum collaboration in the completion of approved projects. will Canada Genome partnerships. funding and scientific for opportunities and projects, special as or ICIs its through either funding, for requests into evolve may which opportunities, emerging out seek to continue will Canada Genome GE “Taking for Strategy National • Canada in2009–10,Genomewillworktoward: Genome to funding future on Dependent level. next the to • • bridging the gap between GE and makingitmeaningful; provide relevant GE relevant provide that vehicles outreach public effective encouraging development basedonresearchevidence; issues ofrelevant national interest, with and informing public aligned policy priorities research guiding at aimed initiatives various through policy public GE public and actively engage their views and interest on GE effective performance indicators develop for measuring and to evaluating process expert an initiating integration of GE the strengthen to initiatives continued encouraging 3 3 LS issues, and enhances visibility of GE LS success; Canadian public. the to genomics of successes and rewards risks, relative the of communication legal, social and other issues related to genomics research (GE research genomics to related issues other and social economic, environmental, legal, ethical, of area the in leadership of assumption The Objective 4: The encouragement of investment by other in the field of genomics genomics of field the in research. other by investment of encouragement The Objective 5: 3 LS Strategy for taking GE taking for Strategy LS 3 LS in large-scale genomics projects 3 LS information to the general general the to information LS 3 LS research and federal 3 LS leadership LS 3 LS research; 3 LS LS

• • implemented in2009–10. and developed be will plan communications revised A results will continue to be priorities for Genome Canada.and role its about government federal the informing and public the to funding research Canada Genome of the informing federal government about Communicating the benefits and public the Canada to Genome funding of research benefits the Communicating Education andPublicOutreach conceptualizing, planning and organizing a GE international organizing signature and planning conceptualizing, take stock of 10 years’ worth of GE of worth years’ 10 of stock take enabling a vibrant GE vibrant a enabling application; results and mobilize the next phase of uptake and and amongrelevantstakeholdersacrossCanada. disciplines relevant across community broader SECTION 1V–Plansfor2009–10 3 LS network and sense of of sense and network LS 3 LS event in 2010 to to 2010 in event LS 3 LS), and the the and LS), 3 LS research LS

29 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 28 GENOME CANADA — Corporate Plan 2009–10 SECTION 1V– 3 Genome Canada recognizes the importance of launching, of importance the recognizes Canada Genome However, time. this at research discovery to dedicated Genome Canada will not proceed with an open competition (Under development) Competition Frontiers Genomics New child healthatthistime. in research genomics applied on competition strategic a of launch the with proceed not will Canada Genome date, to- progress and work significant the Notwithstanding Competition (Underdevelopment) Health Child in Research Genomics Applied and terrestrialanimalsatthistime. aquatic in research genomics applied on competition tegic Genome Canada will not proceed with the launch of a stra Notwithstanding the significant work and progress to-date, development) Competition Animals Terrestrial and Aquatic in Research Genomics Applied begin. will competition crops and bioproducts the for projects all of oversight and management and released be will Funds or CropsCompetition(Ongoing) Bioproducts in Research Genomics Applied for funding. to emerging opportunities, which may evolve into requests Genome Canada will continue to seek out and be responsive Emerging Issues in 2009–10. receipt of some final reports which are due to be completed the for preparation including III Competition for projects all of monitoring and management ongoing be will There Competition IIIProjects(Ongoing) NATIONAL STRATEGIC RESEARCHPRIORITIES– and thepublic. hospitals research universities, government, industry, together bringing by Canada to importance strategic of projects large-scale of support The Objective 3: Plansfor2009–10 (Ongoing) (Under -

• • • • As for the funded ICIs (SGC and P and (SGC ICIs funded the for As input. expert appropriate with proposals the of review the during the development of the full proposals and will conduct Genome Canada and its partners will support the applicants development, under ICIs those For ICIs. new for Intent of Letters review and accept to continue will Canada Genome Initiatives International Consortium INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– research competitions. applied or strategic include also would which portfolio periodically, open competitions as part of a balanced research activities areplanned: specific following The meetings. Committee Management and Committee Steering Board, Advisory Scientific International Directors, of Board the in participation through oversight on-going the in involved be to continue (Ongoing) development) International Barcode of Life (iBOL) development) (Under (IRC) Consortium Regulome International Public Population Project in Genomics (P (Ongoing) (SGC) Consortium Genomics Structural Advisory Board,andSteeringCommitteemeetings. Advisory Science International Annual, Board, at participation as well as oversight of the activities of the IRC through international peer review committee’s recommendations the of follow-up possible IRC, the of review Directors' Science Advisory Board,andmanagement meetings. Science Advisory through participation in Board, Annual, International ongoing oversight of the activities of the iBOL project. as well as recommendations committee’s review peer protein structuresareontrack. three-dimensional of determination the for stones —oversight of the activities of the P the of activities the of —oversight mile target that ensure to —oversight —follow-up of the international the of —follow-up 3 G), Genome Canada will Canada Genome G), —Pending Board of of Board —Pending

(Under 3 G) G) 3 G - established established Canada’s leadership in GE has Canada Genome history, short relatively its Over • • • • • advisors totheBoardofDirectors. Humanities Research Council—are non-voting, ex-officio and Sciences Social and Council, Research Engineering Research, National Research Council, Natural Sciences and Health of Institutes Canadian Innovation, for Foundation Canada agencies—the research federal major five of Presidents The communities. sector public and private comprising up to 16 individuals drawn from the academic, Directors of Board a by governed is Canada Genome and anannualreport. plan corporate a of submission the of way by Industry of Genome Canada reports to Parliament through the Minister Governance position intothenextphase. leadership its take to Canada Genome for actions and comprehensive a of implementation and development the with area this in effort its consolidating is Canada Genome research. proteomics and genomics with associated implications the World HealthOrganizationcalled“stunning.” allowed the sequencing of the SARS virus, at a speed that one the as such projects, research genomics sophisticated equipment serve numerous large-scale and machines sequencing where Columbia, British creating state-of-the-art facilities such as the one in of developingbiotechnologyinAfrica; benefits the enabling in leadership global providing Newfoundland’s fishingindustry; stress or disease, creating opportunities to revitalize to resistance and growth for responsible genes identify to cod Atlantic the of genome the mapping temperatures, promising a new approach to forestry; higher or drought pests, to resistant more are that trees grow to tools genomics of development world’s mosteconomicallyimportantfruit; the grape, wine the of genomics the into research GE 3 strategy that will identify priorities LS strategy that will identify 3 LS LS and the potential SECTION 1 GOVERNANCE STRUCTURE GENOME CANADA areas ofgenomicsandproteomicsinCanada. integrated strategy for research and development in the an on expertise and advice visionary and strategic and Industry Advisory Committee (SIAC) that provides Science a established also has Directors of Board The and CompensationCommittee. Election Committee, Corporate Governance Committee Committee, Investment Committee, Audit Committee, Executive an including duties, its discharge it help to committees of number a establishing Canada, the stewardship of the business and affairs of Genome for responsibility overall has Directors of Board The COMMITTEE COMPENSATION COMMITTEE INVESTMENT COMMITTEE EXECUTIVE DIRECTORS BOARD OF MEMBERS – AboutGenomeCanada COMMITTEE GOVERNANCE CORPORATE COMMITTEE ELECTION COMMITTEE AUDIT

COMMITTEE ADVISORY INDUSTRY SCIENCE & GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 5 6 GENOME CANADA — Corporate Plan 2009–10 SECTION 1– who provide expertise in the delivery of specialized services, areusedonanas-neededbasis. ofspecializedservices, who provideexpertiseinthedelivery Consultants, environment. research ever-changinggenomics an to adaptability and response rapid and nimble for allowing Canada maintains a small staff complement and works within an organizational structure that has few management layers thus comfortable working and collaborating with colleagues and associates at provincial, national and international levels. Genome are who expertise of areas specialized and records track solid with players team results-oriented of CEO,cadre a represents The President and CEO reports to the Board of Directors. The management team, which reports directly to the President and VP Communications Communications VP Claudine Renauld Claudine Communications Communications & Public Affairs & Public Coordinator TBD CONSULTANT AboutGenomeCanada Chief Administrative Officer Administrative Chief GENOME CANADA ORGANIZATION Carol Anne Esnard AnneCarol Marc DesmaraisMarc VP Government VP GennyCardin Director, Operations Director, Relations Analyst HélèneMeilleur Administrative Assistant Administrative Administrative Officer Administrative BrigitteVaillant Julie Julie Bernier Corporate Development Corporate Genomics Programs Genomics Director, National Director, Program Manager Program Program Manager Program Barbara Francis Barbara Executive VP Executive KarenDewar Cindy Bell Bell Cindy KateSwan Board Board of Directors President and CEO President Martin Godbout Martin Director, International Director, Genomics Programs Genomics Program Manager Program Genomics Program Genomics Kim Kim Corbett TBD TBD VP Chief Scientific Officer Scientific Chief Program Administrator Program Shannon Mondoux Shannon Michael Michael Morgan Data Data Manager Tech.Development Patricia Kosseim Patricia Kosseim GE ChuckHasel Consultant 3 Chief Chief LS LS Officer Normand Therrien Normand Financial Officer Financial Robert Moreau Robert Guy D’Aloisio Comptroller Finance VP VP JANUARY 2009 JANUARY 2 in delivering high-quality technology services. in deliveringhigh-qualitytechnologyservices. communication, and sharing best methods and practices platforms, discussing methods to improve cross-platform the by made technologies in advances of details sharing of purpose the for platforms Canada-funded Genome six the of leaders the of meeting annual an be will there maximum access and usage of the platforms. In 2009–10, platform leaders, Genome Canada will continue to ensure S&T the and Centres Genome the with collaboration In Platforms Technology (Ongoing) and Science and abstractspresentedatmeetingsconferences. reports, publications, as such outcomes project any of Canada maintains proper financial Genome oversight as that well as awareness ensure will This milestones. to progress describing reports through quarterly projects development technology successful the monitor will Canada Genome Centre, Genome each with Working Projects Development Technology of Management support. oversight of operational and to project respect management with funding 2009–10 in Centres Genome the with Genome Canada will continue to work in close collaboration Genome Centres and theAtlantic. are there which currentlyof six, one each Canada, in British Columbia, across Alberta, the Prairies, Centres Ontario, Quebec, Genome regional through areas The provision of leading-edge technology to researchers in all genomics-related Objective 2: (Ongoing) (Ongoing)

SECTION 1V–Plansfor2009–10

27 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 26 GENOME CANADA — Corporate Plan 2009–10 and global scientific and socio-economic impact,andthereceiptbyGenomeCanadaofnewfunding support. and globalscientificsocio-economic national for potential the of assessments relevance, and merit scientific of assessments reviews, peer international of outcomes Implementation of many of the proposed major research initiatives is contingent upon a number of factors, including the successful future investmentsbereflectiveofpriorities,asdeterminedbytheBoardDirectors,anddelivervaluefortaxpayers’dollars. The following section outlines Genome Canada’s planned activities for 2009–10. These plans align with its strategic approach that activities withrespecttoassessingresultsoftheresearchithasfunded. several undertake will Canada Genome consortia. international with engage actively and ICIs, of development the in assist and met and to areas identify for improvement. Genome Canada will continue to consult broadly with its research community, assess on-going monitoring and interim reviews of its large-scale research projects and S&T platforms in order to ensure milestones are and proteomics research in Canada, aligning its activities to its five national objectives. It will continue to conduct, as required, In 2009–10, Genome Canada will continue to deliver its mandate as the primary funding and information resource for genomics ACTIVITIES ANDEXPECTEDRESULTSPLANNED FOR2009–10 SECTION 1V 1 NATIONAL STRATEGIC RESEARCHPRIORITIES– international initiatives: and support of the following new and ongoing national and in some instances take a leadership role, in the development Genome Canada will continue to be an active participant, and International CollaborationsandInitiatives INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– and isconfidentitwillbeabletoproceedinduecourse. process valuable and important this to committed remains Canada Genome time. this PositionPaperat Processthe of to-date, Genome Canada will not proceed with the third cycle Not withstanding the excellent work and significant progress Position Papers(Underdevelopment) agriculture, environment, forestry andfisheries. forestry agriculture, environment, health, as such areas in leader world a become to Canada enable to research genomics for strategy coordinated a of establishment and development The Objective 1: – Plans for2009–10

Polar GenomicsWorkshop (New) • Data ReleaseWorkshop (New) • 4th InternationalGenomeCanadaConference • conferences andsymposia,includinga: workshops, international and national co-sponsor and host organize, to continue will Canada Genome Conferences andSymposia National andInternationalWorkshops, Canada–Chile Partnership (Under development) • Canada–Italy Partnership • International • Cancer StemCellConsortium • International Funders’ Forum • International • • (Under development) Turning DataintoKnowledgeWorkshop Knockout

Cancer

Mouse

(Under development) Genome (Ongoing) (Ongoing) Consortium

Consortium (New) (Ongoing) (New)

2 1

"Genomicsmeansthestudyofgenesand their functions,namelygenomics,proteomics,genotyping,sequencing, Genome Canada’sF March 30,2008). bioinformatics andotherrelatedfields ofresearch(asperthedefinitionstatedinFunding Agreement signed objectives: The reportingofplansandactivitiesinthiscorporateplanisorganizedaroundGenomeCanada’sfive outlines anticipatedplansandexpectedresultsforthefiscalyear2009–10. Genome Canada’sCorporatePlan2009–10reportsonactivitiesandperformancefor2008–09, ABOUT THISDOCUMENT 3 4 2 5 1 1

unding AgreementsignedMarch31,2008 social and other issues related to genomics research (GE the assumption of leadership in the area of ethical, environmental, economic, legal, together industry, government,universities,researchhospitalsandthepublic; bringing by Canada to importance strategic of projects large-scale of support the each inBritishColumbia,Alberta,thePrairies, Ontario,Quebec,andtheAtlantic; through regional Genome Centres across Canada, of which there are currently six, one the provision of leading-edge technology to researchers in all genomics-related fields andfisheries; environment, forestry agriculture, health, as such areas in leader world a become to Canada enable to the development and establishment of a coordinated strategy for genomics research the encouragementofinvestmentbyothersinfieldgenomicsresearch. of the relative risks, rewards and successes of genomics to the Canadian public; and SECTION 1 – 3 LS), and the communication About GenomeCanada

2 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 7 8 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I mandate andobjectives. its of fulfillment in 2008–09 for accomplishments and activities major Canada’s Genome outlines section This stage. research in Canada of genomics and proteomics research capacity and to affirming Canada’s stature on the world’s genomics and proteomics Since its creation in 2000, Genome Canada has been committed to encouraging, developing, facilitating and financing the expansion 1 a number of specific areas (health, agriculture, environment, forestry, fisheries, new technologies, and GE and technologies, new fisheries, forestry, environment, agriculture, (health, areas specific of number a in Canada is to assume the role of facilitator or leader, bringing together select Canadian and international groups from Genome Canada’s approach for developing and establishing a coordinated strategy for genomics and proteomics research Strategy forsuccess forums, eventsandresearchprojects. international in participation and Canada, in workshops and conferences of hosting engaged the researchers, included with interaction 2008–09 in Activities research. proteomics and genomics of fields the in interests common have What wasachieved NATIONAL STRATEGIC RESEARCHPRIORITIES– and impactsonthesectorordiscipline. outcomes outputs, socio-economic expected the and years, four over required funding total estimated the Canada, in available capacity resources human and infrastructure the abroad, and Canada in science the provide solutions. It must describe the current state of to bear to brought be can tools genomics/proteomics how and tackled, be to problem(s) the of importance of series a in the define must paper position The papers.” “position described be will themes research strategic These Canadians. to importance economic in nationally recognized areas of interest and of socio- themes research strategic to targeted be will funding that states process the of premise fundamental The years. subsequent and 2008 for research proteomics and genomics in investment future of allocation the optimize to approach new Papers—a Position for In 2006–07, Genome Canada launched the first Request Position Papers(Ongoing)— agriculture, environment, forestry andfisheries. health, forestry agriculture, environment, as such areas in leader world a become to genomics Canada for enable to strategy research coordinated a of establishment and development The Objective 1: – Pursuing ourObjectives:

Performance for2008–09 or CropsinApril2008. Competition in Applied Genomics Research in Bioproducts Genome Canada in the 2008 federal budget led tothe launch of a for funding additional of announcement An in Canada’sFuture). Children’s Health (Child Health Genomics: An Investment and Genomics) TerrestrialAnimal and (Aquatic Animals Agriculture– of areas the on focused forward carried be to recommended papers the 2008–09, In Genomics). through Economy Bio-based Future Canada’s (Securing Agriculture–Plants Bioproducts and Canada) Healthy a for Genomics of (Crop themes the addressed papers Industry Canada. In 2007–08, to the recommended submission position budget and portfolio research strategic Genome Canada for inclusion in Genome Canada’s annual of Board the to recommended were papers position two the in Following aninternational summer of2008.peerreview, papers position completed of submission and production the manage to agreed who leaders selected Participating papers. position writing then communities and (EOIs) Interest of Expressions submitting by themes research strategic identify to stakeholders other with join to community scientific the invited Canada Genome 3 LS) which LS) * As at February 2009 * AsatFebruary Closing CashBalance Opening CashBalance Revenue overDisbursements Excess (deficiency)of Total Disbursements OperatingExpenditures ResearchProjects PROGRAM AND OPERATING DISBURSEMENTS InvestmentIncome GovernmentofCanada REVENUES DISBURSEMENTS TODATE SUMMARY OFREVENUESAND DETAILS (inmillionsofdollars)* GenomeCentres(6) GenomeCanada NewTechnology Development C.difficile CompetitionI S&T Platforms Public Population Project inGenomics StructuralGenomicsConsortium BovineGenomeSequencingProject AppliedGenomicsinHumanHealthCompetition CompetitionIII CompetitionII

International RegulomeConsortium Genome Canada-Genoma EspañaCompetition Genome Canada-Genoma International BarcodeofLife

SECTION 1II–GrantManagementfor2008–09

Projects Funded 128 119 10 33 33 14 13 17

3 1 1 1 1 1 1 to 2007–08 ACTUALS 689.2 585.0 2000–01 426.3 104.2 104.2 69.8 88.9 606.7 146.9 105.5 48.0 80.6 40.9 82.5 57.7 16.3 6.0 0.2 4.3 7.7 0.1 1.0

29.5 (56.6) FORECAST 104.2 60.8 88.0 47.6 2008–09 12.0 (0.7) 15.2 31.4 45.1 6.0 9.2 6.3 2.3 2.2 0.1 0.1 4.1 1.9 1.3

CUMULATIVE FORECAST to 2008–09 720.6 673.0 487.1 104.1 47.6 47.6 636.2 150.6 146.2 81.8 84.4 80.6 46.9 59.9 22.6 57.2 6.0 6.6 0.2 4.3 2.3 7.7 0.1

25 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 24 GENOME CANADA — Corporate Plan 2009–10 SECTION 1II– 2000 Funding andInvestments Canada’s financial statements present fairly, in all in fairly, present statements financial Canada’s Genome whether on opinion an express to is objective The standards. auditing Canadian accepted generally within 45 days of each fiscal year-end in accordance with February for review and approval. The audit is conducted in Committee Audit Canada’s Genome to plan audit an 2008–09 are KPMG LLP. Auditors are required to submit audit of its financial statements; the external auditors for Canada selects external auditors to undertake an annual Genome organization, incorporated not-for-profit, a As Annual Audits submission beforereleasingfunds. request draw the of review thorough a conducts Canada Genome sources. other from received co-funding and reports progress scientific expenditures, actual budget, approved the against needs project/platform the assess Centres Genome quarter.The subsequent the for Centre the of needs cash the indicating Canada Genome to request” “draw a submits then It manages. it that estimate cash requirements for each project and platform and date to expenditures review to required is Centre Genome Each platforms. S&T and projects research approved for Centres Genome regional six the through basis quarterly a on funds disburses Canada Genome Cash Management FEDERAL BUDGET LAUNCH 2000 $160M GENOME CANADA 2001 Grant Managementfor2008–09 PROJECTS BEGIN COMP I COMP FEDERAL BUDGET $140M 2001 2002 PROJECTS BEGIN COMP II COMP FEDERAL BUDGET 2003 $75M 2003 FEDERAL BUDGET 2004 2004 $60M PROJECTS PROJECTS CANADA/ BEGIN SPAIN PROJECTS PROJECTS BEGIN APPLIED APPLIED HEALTH FEDERAL BUDGET $165M 2005 2005 PROJECTS PROJECTS COMP III COMP BEGIN completed todate. being six of total a with 2008–09 and 2007–08 in undertaken been have projects individual on audits Recipient administered. is research proteomics and genomics which within framework control ment manage the improve to and Canada across audits introduced to bring a common approach to recipient was framework This audit. compliance detailed a undergo will that platforms and projects identify to Centres the enable to developed was tool assessment with the Genome Centres. As part of this exercise, a risk FrameworkAudit Recipient consultation a in mented imple and developed Canada Genome 2006–07, In Recipient Audits in Juneforapproval. Directors of Board the to then and Committee Audit the to presented are findings audit of summary a completion of the audit, the financial statements and Upon corporation. the of flow cash and operations, of results position, financial the respects, material 2006 FEDERAL BUDGET COMP I&II COMP PROJECTS PROJECTS $100M 2007 ENDS 2007 & CANADA/ PROJECTS PROJECTS APPLIED APPLIED FEDERAL HEALTH BUDGET ENDS SPAIN $140M 2008 DEVELOPMENT TECHNOLOGY 2008 PROJECTS BEGIN 2009 BIOFUELS BIOFUELS PROJECTS & CROPS BEGIN 2010 - - PROJECTS PROJECTS COMP III COMP ENDS • collaborations: instances took on a lead role, in the following international some in and participant, active an was Canada Genome International Collaborations INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– received fromthepeerreviewpanel. comments to according revised be or submitted, as ation consider for process the in remain either will years two The remaining five position papers developed over the past round. third this in considered not were health children’s and agriculture–animals agriculture–plants, products, bio as themes research strategic Such 2008. November in launched was PositionPapersexercise for Request third the criteria, selection and guidelines revised by Supported Position Papers 09 cnet o te nrnt ie en developed being site intranet the for content spring 2009; for scheduled workshop, release data the of planning the on focused Discussions agencies. funding respective their of initiatives ongoing and the mandates on briefly presented participants International present. were States United the and Kingdom United the Sweden, Spain, Norway, Netherlands, Italy, the Japan, Germany, Commission, European the Canada, China, from Representatives Vancouver. in 2008, the hosted 21, October Canada on Forum Funders’ Genome International second site. intranet an of establishment the and release, data on workshop a as well as Forum Funders’ International annual an of from the first meeting, which included the organization recommendations the action to mandated committee steering Canada-led Genome a of establishment the was outcomes the Among City. Quebec in 2007, 16, October on held was forum the of meeting first The collaboration. future for opportunities identify to and projects, these of funding the around issues discuss to projects, genomics international large-scale of funders the among communication and awareness increase to is Forum Funders’ International the of purpose The International Funders’ Forum (Under Development) SECTION 1I – Pursuing our Objectives: (Ongoing)

— - - • • metrics and intellectual property management. evaluation publications, research to access to medium for scientists in Canada and California collaborative a offers directors, of board a by governed is which CSCC, The Canada. Genome and Research, Cancer for Institute the Ontario Network, Cell Stem the Innovation, for Foundation Canadian the Research, Health of the consortium include the Canadian Institutes of Members 2007. November in incorporated formally was (CSCC) Consortium Cancer Cell the Stem agencies, funding and cell experts stem cancer Californian and leading Canadian between meetings and discussions (Ongoing) Consortium Cell Stem Cancer secretariat support. providing Canada Genome with committee steering the of chair as researcher Canadian leading a of appointment the included 2008, meeting that took place IKMC in Toronto on May 13, the of consortium’s Outcomes the committee. steering of member a is Canada Genome mutagenesis. mouse of area the in collaboration international coordinating for vehicle a and as serves biology consortium The disease. human into insight provide will out” “knocked genes specific with mice Studying (IKMC). Consortium Mouse Knockout International the constitute that mutagenesis mouse in projects international Texaslarge-scale four the are the Medicine Genomic and of Institute Project American-led Mouse the Knockout Program, Mutagenesis Mouse Project, Conditional European the with Mutagenesis along Mouse Conditional Consortium International KnockoutMouse with support from the from support with h Gnm Cnd-udd ot American North Canada-funded Genome The recherche recherche recherche

Performance for 2008–09 (France); and specific topics related topics specific (France);and Bidn o to er of years two on —Building (Ongoing) Agence nationale de la la de nationale Agence

— GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 9 10 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: June 2008. The CSCC Board is currently developing currently is Board CSCC The 2008. June in organizations two the by signed Understanding of Memorandum the from resulting initiative first the is This research. cell stem cancer on focusing scientists Californian and Canadian of Teams Disease support to Medicine Regenerative for Institute California the and CSCC the by issued was applications for call joint a 2009, February In grants. investigator-initiated individual through feasible not approach large-scale goals that can best be achieved by using an integrated with teams research of development the encourage to applications for requests coordinate members jointly will CSCC The research. cell stem cancer to related issues social and legal ethical, address that those including disciplines, of range wide a across adopt, as a fundamental principle, open collaboration and approaches diverse of development the embrace pursuing common research goals. The and Consortium will platforms technology cutting-edge sharing by biology CSC in advances basic to data clinical patient link to teams research enable will efforts large-scale of support The applications. clinical into findings research translate to and study for CSCs live provide to developed be will infrastructure State-of-the-art on identifying CSC biomarkers and anti-CSC therapies. focus will CSCC the of programs research The years. it will undertake to achieve its goals over the next five activities research of sequence the defines it as CSCC and Californian scientists, will guide the Board of the CSCC Strategic Plan, developed by The a team of Canadian research. cell stem cancer support to contribute funding and consortium the join cancer to companies non-governmental organizations and pharmaceutical and biotechnology agencies, funding provincial and federal as such entities private and in the development of the consortium, inviting public role lead enduring a playing is Canada Genome offer cures. cancer potentially will eradication their and metastases, and growth tumour for accounting cancers, many its of root the at culprits major the be to and research cell considered are (CSC) cells stem stem Cancer applications. cancer on focus to

Performance for 2008–09 • •

Consortium. the of members potential other identifying as well as plan, strategic its of components other implement to (2009–2014) Plan Operational its o adtoa Cnda priiain n the in consortium. participation Canadian additional for opportunities exploring also is Canada Genome funders, Canadian other with Along Committees. Planning Science and Executive the both through consortium the of development the in role active an played have staff Canada Genome ICGC, the States. in status United observer has Canada Genome Although the and Kingdom, United the Spain, Singapore, Japan, India, France, China, Australia,Canada, Countries include ICGC the cancer. in involved in abnormalities genome (somatic) of atlas was an produce to is consortium (ICGC) the of goal The Consortium 2008. April in launched formally Genome Cancer International Cancer Genome Consortium Canada–Italy Partnership Canada–Italy (Under development) (Under (Under development) (Under future collaboration. The workshop participants workshop The collaboration. future to human health and to opportunities identify for related research proteomics and genomics scale activities in Canada and Italy in the area of research large- current of awareness increase to was workshop the of objective The 2008. 7–8, April Rome, in workshop a in participated Italy from number equal an and Canada from funders of representatives and scientists 40 approximately a first step in strengthening this new partnership, As health. and human to related research proteomics genomics large-scale of area the in Italy and Canada between framework collaborative a establishing and linkages existing expanding of objectives the with (CNR) Council Research between Genome Canada and the Italian National 2007 of fall the in signed was Understanding of —The International —The —A Memorandum

levels ofgovernmentandfromtheprivatesector. other from funds additional leverage to ability the has also It investment. judicious and careful through government federal the from receives it grants the maximize to flexibility the has Canada Genome organization, not-for-profit,arm’s-length a As Canada. Genome CanadaandIndustry between agreements funding through formalized grants, conditional of form the in come has funding All years. five next the over Canada Genome of requirements cash annual the on based paid be now will funds these policies, government new with accordance In 2008. February of budget federal the from $140M the and 2007 March of budget federal the in announced was that $100M the of exception the with indicated, years the in sum lump one in provided was funding This 2007–08. in $140M and 2006–07 in $100M 2005–06; in $165M 2004–05; in $60M 2003–04; in $75M 2001–02; in $140M 2000–01; in $160M The federal government, through Industry Canada, has approved a total of $840M in funding for Genome Canada since 2000–01; SECTION 1II Research inHumanHealthCompetition. Proteomics and Genomics Applied the in (2003–06) years three to up for approved were that platforms S&T associated and projects funded ($75M) 2003–04 in government federal the from received grant The operations of Genome Canada and five Genome Centres. the funded also grants These (2002–06). years four to up for II, and I Competitions in approved were that platforms S&T and projects research large-scale the funded ($140M) 2001–02 in and government ($160M) 2000–01 federal the from received Grants Source andUseofFunds the outcomeoftheirdeliberations. committees meet quarterly and report to the Board on Both reporting. financial and auditing management, risk controls, internal and accounting of areas the in activities and processes policies, Canada’s Genome overseeing for responsible is Committee Audit The for the prudent investment and management of funds. policy that outlines guidelines, standards and procedures government according to a Board-approved investment federal the from received funds of management and Committee is responsible for overseeing the investment Investment The management. grant to respect with Genome Canada in fulfilling its fiduciary responsibilities Two Board Committees support the Board of Directors of Investment and Management of Funds – GrantManagementfor2008–09 Technology Developmentprojects. Genomics), as well as a competition in 2007–08 for New Consortium Phase I and the Public Population Project in Initiative, funding for two ICIs (the Structural Genomics Sequencing Genome Bovine the España, Genoma and bilateral research competition between Genome Canada a as Genome such initiatives, research other allowed launch to Canada has investment, federal earned the $80M, with over of earnings investment Federal regional six Genome Centres. the and Canada Genome of operations the and platforms S&T for funding continued as well as Consortium, Cell Stem Cancer the through projects research Crops, and Bioproducts in in Genomics Applied competition a fund will in ($140M) 2008 government February federal the by approved grant The through 2009–10. of Genome Canada and the six regional Genome Centres the Structural Genomics Consortium, and the operations projects, the S&T platforms through 2008–09, Phase II of 2007 ($100M) will fund the fourth year of Competition III The grant approved by the federal government in March S&T platformsuntiltheendoffiscalyear2007–08. six of renewal the and years, three for Centres Genome six and Canada Genome of operations the years, three for III Competition in successful were that projects the funded ($165M) 2005–06 in and ($60M) 2004–05 in government federal the from received grants The

23 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 22 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: 5 from abroad. and Canada within from contributions for commitments researchers, the and Centres Genome the through and/or itself is to continue developing collaborative relationships with the private, public and philanthropic sectors as well as to secure, by others. Genome Canada’s strategy to encourage investment by others in excellent large-scale genomics research projects Genome Canada funds up to 50% of the eligible costs of research projects, with the remainder secured through co-funding Strategy forsuccess funders asshowninthefigurebelow. co- with funded jointly being are and have which $1.5B totaling projects approved has Canada Genome 2000, Since What wasachieved Note: INSTITUTIONAL INSTITUTIONAL of Genomicsresearch. field the in Persons other by investment of encouragement The Objective 5: FUNDING SOURCESFOR Figure above does not include funding and related co-funding ofGenome Centres. Figure abovedoesnotincludefunding andrelatedco-funding 5% 5% FEDERAL FEDERAL 7% 7% INDUSTRY GENOMECANADA 10% GENOME CANADA GENOME CANADA 44% GENOME CANADA 44%

Performance for 2008–09 PROVINCIAL 13% -APPROVED PROJECTS FOREIGN 21% 21%

• addressing aquaticanimalhealth. proteomics and genomics in program bilateral a develop to and Chile with DFO working are result, Canada Genome a As time. this at Canada with initiative international joint large-scale a pursue to had Spain the nor interest Norway nor the resources neither that clear was it workshop, as the of result a researchers Chilean and Norwegian Spanish, and community research Canadian the of members between developed collaborations individual some and to determine a mechanism to achieve this. While research genomics collaborative international from key identify questions in to aquatic animal health were that would benefit objectives Their Chile. and Health” Animal Norway Spain, Canada, from participants involving Aquatic Improve “Applied to on Genomics workshop international an hosted co- DFO and Canada Genome 2008, 25–27, June on Barcelona In needs. and opportunities Canadian Canadian define to together industry aquaculture bring the and to scientists 2008, 1, May on Ottawa in workshop a organized DFO and Canada been extended to include Norway and has Chile. Genome that proposal a Spain, with aquaculture and joint international initiatives in the area of genomics possible explore to (DFO) Oceans and Fisheries of Canada initiated a collaboration with the Department Udr development) (Under Canada–Chile Partnership Canada–Chile Partnership Intent in February 2009. Intent inFebruary of Letters of receipt the was competition a such of development the in step first The available. is joint competition which proposed will be launched if a future funding for staff guidelines developed CNR have and Canada Genome strengths. and interests identified common, of areas several projects in research joint support to developed be should Applications for Request joint a that agreed SECTION 1I – Pursuing our Objectives: I 20, Genome 2007, —In ainl n itrainl okhp, ofrne and symposia, includingthe: conferences workshops, international and national Genome Canada continued to organize, host and co-sponsor Conferences andSymposia National andInternationalWorkshops, • • over thenextdecadeandbeyond. research genomics of future the and diseases childhood of role the government science advisors, stem cells, the genomics of discovery, drug and commercialization variation, genetic human to related topics and on presenters speakers keynote featured than and more participants 225 attracted conference third and This society law. the ethics, economy, the to environment, relates it the how on but bioscience, of world the on just not have, will work this impact the and research genomics in trends future on focused theme conference Vancouver.The in 2008, 22–24, October on on Society— Science of Impact The Vision: conference—2020 international Canadian third its held Canada Genome and the impact of current GE current of impact the and issues highlights, on focused Discussions landscape. Making aDifference. of the closing session entitled Knowledge Translation— website (www.genomecanada.ca), together with a report Canada’s Genome on available publicly are symposium the from posters and abstracts conference biographies, Presenters’ sessions. poster the and presentations oral the both during research discussions the of in engaged number trainees, significant a including the across globe, from participants 150 Over beyond. and community Canada Genome the in agendas research changing drive to likely opportunities and needs new nentoa G³S ypsu 2008 Symposium (Completed) GE³LS International Conference 3rd GenomeInternational Canada event offered a comprehensive overview of the GE the of overview comprehensive a offered event three-day The 2008. 28–30, April on Calgary in place Landscape—took Changing the 2008—Navigating

Performance for 2008–09 (Completed) —The International GE³LS Symposium 3 LS research, as well as well as research, LS —

3 LS GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 11 12 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: • •

not playanactiveroleintheseactivities. approach. Genome Canada determined that it would step to demonstrate the feasibility and utility of this developed and implemented a pilot project as a first scientists of group small a workshop, the Following of the cost/benefit analysis of the various approaches. value and utility; it would also enable an assessment them and assessing which leads would be of greatest human characterizing for of way leads agreed-upon proteins—an new validate and identify to mechanism a of establishment the for allow would consortium The proteins. human for probes specific and selective develop to consortium international an creating of possibility the explore to Sweden, A workshop was held March 15, 2008, in Stockholm, international genomicsresearchcommunity. the by used be to data of types specific for practice and to produce guidelines for what this will mean in recommendations to encourage rapid release of data developing on focus will 2009, Spring for planned workshop, The workshop. release data international an of development the leading is Canada Genome Forum, Funders' International the of aegis Under Data ReleaseWorkshop(New) Protein Ligand Workshop (Completed) —

Performance for 2008–09 — • • • • international genomics andproteomicsconferences: following the at presence the followingyoutheducationprograms: Genome Canada showed its support or or support its showed Canada Genome Conference Support In 2008–09, Genome Canada partnered with Programs Partnering withYouth Education • • • • • • • • • the Sanofi–Aventis BiotechChallenge, the Canada-wideScienceFair, which Spring 2008. the country, May2008; best scienceprojectsfromacross attracts high-schoolstudentswiththe Summer 2008 Pharmacology andTherapeutics, The IXthWorld ConferenceonClinical Summer 2008 Amsterdam, Fall2008 India, Fall2008 HUGO (HumanGenomeOrganization), Diego, Spring2008 biotechnology conference),San BIO (thelargestinternational Université LavalCongrésIUFRO, BioContact, QuebecCity, Fall2008 HUPO (Human Toronto,Bio-Finance, Spring2008 SECTION 1I – Pursuing our Objectives: Proteome Organization) ,

• to itsdiverseclientele. trends in this field, but also offers better service It not only responds better to current needs and ever financial database and a search capability. spring of 2008. The new website includes a first- Canada the in website new a Genome launched and developed website, its of look and In order to improve the content, navigability content, the improve to order In Website

Performance for 2008–09

21 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 20 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I–Pursuing ourObjectives: • •

(Ongoing) New GE New which include: strategy this of components various the implement ongoing basis over the next two years and beyond to and networking across the broader GE consultation, and promote a virtual space for dialogue and input for vehicle a manner,as timely a serve in information relevant exchange to launched be will GE new a 2009, Spring In GE in Canada. Work on developing and maintaining the policy-makers, themediaandgeneralpublic. researchers, for resource informational meaningful • • • • delivered toallaudiences. regional basis to ensure that a consistent message is a on tools and activities these using or developing, managing in collaborators been have Centres partners and other key stakeholders. The six Genome government policy and decision-makers, researchers, parliamentarians, media, public, the to targeted are initiatives These tools. and activities outreach public and communications unique and innovative implemented and developed has Canada Genome research, proteomics and issues genomics surrounding important the understand to Canadians assisting of objective national its to response In Education and Public Outreach • • • 3 LS webpage will continue in order to provide a provide to order in continue will webpage LS supporting measuring andevaluating strengthening the showcasing Canadian research resultsintoaction enabling a vibrant international stage bringing GE bridging the 3 LS Webpage at Genome Canada Genome at Webpage LS 3 GE LS research results GE 3 LS 3 LS research-publicpolicygap researcherstotranslate GE GE 3 3 LS integrationmodel GE LS network across Canada 3 LS @ Genome webpage Genome @ LS 3 LS GE researchonthe 3 home LS success 3 LS community to Canadians (Ongoing) Performance for2008–09 • •

in Genome(seebelow). GEEE! The exhibition the to pertaining press conference another organized also Canada Genome Consortium. Cell Stem Cancer the of creation the announcing California from representatives and Health, of Minister TonyClement, Honourable the Canada participated in a joint press conference with Diego Biotechnology Industry Conference, Genome San 2009 the during 2008, 18, June On projects. development technology 13 in investment $9.37M a announce to Industry, of Minister the of behalf on Ablonczy, Diane Honourable the Tourism, and Business Small of Minister the with conference 30, 2009. will welcome the exhibition from January 15 to April Mines Thetford de minier et minéralogique Musée for the summer and to Thunder Bay for the fall. Le Deer Red to on moved then exhibition Genome in exhibition in the history of the Museum. The GEEE! visited most third the was exhibition The Science. of World Edmonton TELUS the at media, the by attended ceremony, official an during exhibition the opened Diversification) Economic Western of (Minister of Intergovernmental Affairs and Minister 2008 in Edmonton. The Honourable Rona Ambrose second three-year cross-Canada tour on March 19, 2500-sq-ft bilingual travelling exhibition, started a The GEEE!InGenome media coverage. by the national and international media for broad releases in fiscal year 2008–09 that were picked up News Releases and News Conference On May 5, 2008, Genome Canada held a news news a held Canada Genome 2008, 5, May On The GEEE! in Genome, a refurbished and updated and refurbished a Genome, in GEEE! The press six issued partners and Canada Genome 2 manage andmonitornew, large-scaleresearchopportunities,andassistinfundraisingactivities. and genomics- all in proteomics-related areas, the researchers Centres facilitate access For to leading-edge Genome projects. Canada fully funded research S&T platforms, identify, proteomics and genomics large-scale manage and in co-invest that organizations not-for-profit are Centres Genome These Canada. across region each in Centres Genome support to is Genome Canada’s strategy to ensure effective management and monitoring of its funded research projects and S&T platforms Strategy forsuccess What wasachieved Genome Centres addition of a separate allocation of funding for the the for funding of management ofprojects. allocation separate a of addition the with along Centre, each of expenses administrative general support to funding of amount base new a reflect to model funding the to adjustment an included Results Centres’ the abilities to deliver on their disrupting individual funding agreements. without efficiencies gain and services improve to ways determining as well as funding delivery service current of review a included discussions These model. funding Centre Genome the re-examine to between Genome Canada and the Genome discussions Centres were undertaken 2007–08, In framework. policy national a within operate to Centre each for provisions necessary the provides also but Centre, Genome each of independence the acknowledges that agreement funding a of means by managed is Centres Genome the of each and Canada Genome between relationship business The GenomeAtlantic(Halifax) • GenomeQuebec(Montreal) • OntarioGenomicsInstitute(Toronto) • GenomePrairie (Saskatoon,withasatellite • GenomeAlberta(Calgary) • GenomeBritishColumbia(Vancouver) • Centres, whicharelocatedacrossCanadaasfollows: Genome Canadasupportstheoperationsofsix office inWinnipeg) and theAtlantic. are there which of currently six, one each Canada, in British Columbia, Alberta, the across Prairies, Ontario, Quebec Centres Genome regional through fields The provision of leading-edge technology to researchers in all genomics-related Objective 2:

(Ongoing) SECTION 1I – Pursuing our Objectives:

February 6, 2009. The purpose of this RFA is to solicit solicit to is RFA this of purpose The 2009. 6, February on Canada Genome at due Intent of Letters with Support Operations Technology & Science an for of competition launch open the approved also Board The platforms. S&T currently-funded the for funding interim of year one In June 2008, Genome Canada’s Board of Directors approved (Ongoing) Operations Support Technology and Science for Competition be availableinthelatterhalfof2010. will results their and 2008 July by launched were projects Development Technology 13 All Canada. across platforms Canadian scientific community and the already-funded S&T and update the menu of technologies available to the entire broaden will projects research these from outcomes The 2007. December in Directors of Board the by accepted was which $9.5M), is contribution Canada’s Genome which (of 51 proposals for two years at a cost of approximately $19M Scientific Review Committee recommended funding 13 of the to improve production of large-scale data. An International large datasets, entirely new technologies, and in-lab devices analyzing for and software new genomics instrumentation, of proteomics generation latest the for techniques new processes, existing to improvements such incremental as development, technology of aspects various with deal that proposals solicit to was intent Its 2007. April in launched was Competition Development Technology The (Ongoing) Technology DevelopmentCompetition

Performance for 2008–09

GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 13 14 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: Technology platformsuntilMarch31,2011. and Science six funded currently the for support extend Science and Technology Operations Support, but rather to February for Competition the with proceed its not to meeting, 2009 at agreed, Directors of Board Genome The Canada Competition. Crops or Bioproducts in Research Genomics Applied the from projects pending and projects, III Competition Canada Genome ongoing for support operations, platform S&T for applications January 2010. January for scheduled is workshop next The services. technology high-quality delivering in practices and methods best share to and communication, cross-platform improve to methods discuss to platforms, the by available made day workshop to share details of advances in technologies from the Genome Centres met in January 2009 for a two- members staff and platforms, of representatives other The leaders of the six Genome Canada-funded platforms, Meeting (Ongoing) Leaders TechnologyPlatform and Science Performance for 2008–09 4 • activities: GE national its refine and advance to continued Canada Genome 2008–09, In What wasachieved GE large-scale of support the including elements, various of composed is research proteomics and genomics to related issues Genome Canada’s strategy to ensure Canadian leadership in the areas of ethical, environmental, economic, legal and social Strategy forsuccess credibility andawareness. visibility,establishing at aimed programs outreach public and education innovative develop to is public Canadian the to research proteomics and genomics of successes and rewards risks, relative the communicate to strategy Canada’s Genome Canada-funded projects. 3 LS research projects having national and international impact, and the integration of that that “Difference the on focused participants symposium Genome Canada community and beyond. Finally, the the for agendas research future influence to likely research and explored new trends and opportunities GE In April 2008,Genome Canada hosted an International International GE Participants discussed contemporary issues in GE apply to seek they when have stakeholders various theme of knowledge translation and the expectations benefits therefrom. GE reconnected to tour the abroad and Canada from Researchers Landscape. (Completed) 3 3 3 LS Symposium entitled Navigating the Changing the Navigating entitled Symposium LS LS GE research results in practice and derive concrete research results from around the world. world. the around from results research the Canadianpublic. communication of the relative risks, rewards and successes of genomics to legal, social and other issues related to genomics research (GE The assumption of leadership in the area of ethical, environmental, economic, Objective 4: 3 LS Makes” by exploring the burgeoning burgeoning the exploring by Makes” 3 LS framework with the following following the with framework LS SECTION 1I – Pursuing our Objectives: 3 LS Symposium GE 3 LS landscape and present GE 3 LS •

• d’être.” researchers, technology users, policy-makers an on continue will Work public. general the policy-makers and users, technology researchers, tangible outcomes for relevant audiences, including concrete, into results research translate to efforts systematic and dedicated encouraging also while national strategy for taking National GE Development and Implementation of a GE Recruitment of a Chief GE Chief a of Recruitment In December 2008, Genome Canada supported a supported Canada Genome 2008, December In Chief full-time new, a created Canada Genome the next generation of implementation of a national strategy that defines initiate and develop to mandated been has Officer (Completed) the integral importance of and area this to commitment ongoing and serious Canada. This new position signals Genome Canada’s 2008 for a two-year period. The new Chief new The period. two-year a for 2008 several months, the position was filled in of September process recruitment a After organization. the to continue to support world-class GE world-class support to continue to next level. The overarching theme of this strategy is 3 Officer position to join the senior ranks of ranks senior the join to position Officer LS Performance for 2008–09 3 LS Strategy(Ongoing) GE 3 LS aspects in all other Genome GE 3 LS leadership at Genome GE GE 3 LS to its very “raison 3 LS 3 leadership to the LS), and the 3 LS Officer Officer LS 3 LS research LS GE 3 LS

19 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 18 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: • • initial fundingoftheconsortium. the since made progress the and leaders project the of expertise the timeliness, its ICI, the by undertaken being work the of importance the acknowledged and ICI the for support continued recommended reviewers research team’s ability to achieve future objectives. The the and date to progress evaluate to Montreal, in assess progress against scientific and to was review the of purpose The Toronto. in 2009, 29, January undertaken was review interim An ICI. the of development staged the for funding of year one approved Canada Genome of Directors of Board the 2007, June In development. of stages and tissues different in factors transcription 570 for genes target and proteins interacting identify to are objectives consortium’s the model, primary the as mouse the using and tools genomics and proteomics Employing medicine. regenerative and research cell stem for mammalian cells during development, with implications in regulated is function gene how exploring of goal overarching the with consortium international profit cohort and founding member of P of member founding and cohort population-based a biobank, CARTaGENE the is ICI health and well-being. A key component of the P the of component key A well-being. and health public improve to knowledge new generate will and disease and health to contributions environmental and genetic the of studies needed for numbers sample large the provide will harmonization This biobanks. international different from collected data and of P of goal The (biobanking). genomics population of field the in projects and researchers between collaboration fostering of aim the with consortium international (Under Development) (Under International Regulome Consortium (IRC) (P Genomics in Project Population Public of the P the of 50,000 Quebec citizens aged 40–69. An interim review from samples DNA and material biological and data, assessment health and socio-demographic collect 3 G) 3 G is to facilitate the harmonization of samples of harmonization the facilitate to is G (Ongoing) 3 G ICI was undertaken on April 23, 2008, 23, April on undertaken was ICI G —P 3 —The IRC is a not-for- a is IRC —The G is a not-for-profit a is G GE 3 G that aims to aims that G 3 LS milestones

Performance for 2008–09 3 G • (Under Development) (Under The International Barcode of Life (iBOL) funding support. new of Canada Genome by receipt the and impact, socio-economic and scientific global and national of the scientific merits of the IRC and its potential for of Directors' assessment at its March 2009 meeting successful outcome of the interim review, the Board contingent upon a number of factors, including the remaining four years of the consortium’s activities is the for support funding Future deliverables. and 2009–10. impact, approved funding support for the iBOL for socio-economic and scientific global for potential conservation biologists and many others and has the that the research will be of great value to scientists, 2009 meeting, the Board of Directors, recognizing February its At support. funding new of Canada ICI for six years contingent upon receipt by Genome Review Committee's recommendation to support the the with meeting, 2008 December its at agreed, Directors of Board Canada Genome The Toronto. in 2008, 7, November on experts of committee international an by reviewed was proposal ICI iBOL The partners. funding potential engaging and structures management and governance appropriate developing included this proposal; ICI an of development facilitate to stakeholders key project leaders, Ontario Genomics Institute staff and In 2007–08, Genome Canada worked with the iBOL III. Competition of aegis the under partners and Barcode of Life Network funded by Genome Canada Canadian the of accomplishments technical the on builds Consortium iBOL The years. five within importance socio-economic of species 500,000 over catalogue would which effort, identification species worldwide a initiate to “barcoding” DNA use will that consortium international for-profit —The iBOL is a not- a is iBOL —The

PLATFORM/SERVICES PROVIDED Training • Help Desk • Software Tools • Bioinformatics Platform(Calgary DNA sequencing • Proteomics • Functional Genomics • Genotyping • Innovation Centre McGill UniversityandGenomeQuebec Biobanking • Statistical Analysis • Genetic Analysis • Cytogenomics andGenomeResources • Microarray AnalysisandGeneExpression • DNA SequencingandSynthesis • The CentreforAppliedGenomics(Toronto) Proteomics • University ofVictoriaProteomics Centre Bioinformatics • Gene expressionprofiling • Clone fingerprintmapping • • DNA sequencing Sciences Centre British ColumbiaCancerAgencyGenome Microarray Analysis • Vancouver GeneralHospital (not includingBioinformatics Platform) • Statisticsformostoftheplatformsare basedonaone-yearperiodfrom2007to2008 Notes: TOTAL Table 1-ScienceandTechnology PlatformsUserStatistics SECTION 1I – Pursuing our Objectives: )

Non-Genome Canadarequests Non-Genome Genome Canadaprojectsrequests Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Non-Genome CanadaAcademic Non-Genome Genome Canadaprojects USERTYPE

Performance for 2008–09 (as atNov. 2008) Total Total Total Total Total Total

120 579 567 996 OF CLIENTS NUMBER 1329 646 350 538 543 113 29 26 63 37 70 30 12 13 11 – 4 7 3 3 1

15 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 16 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I–Pursuing ourObjectives: 3 to Genome Canada’s strategy is ensuring that the GE the that ensuring is strategy Canada’s Genome to as well as a due diligence process that examines the excellence of the proposals’ financial and management elements. Central and GE technologies, forestry,new environment, fisheries, agriculture, health, of areas the in proposals for calls issue to is funded are calibre highest the of projects research proteomics and genomics large-scale that ensure to strategy Canada’s Genome Strategy forsuccess and proteomicsresearchareaddressedasanintegratedcomponentofeachproposal. What wasachieved NATIONAL STRATEGIC RESEARCHPRIORITIES– and EvaluationStrategy. implementation of Genome Canada’s Performance, Audit the final reports will be developed as part of the on-going three months of completion. The process for the review of the outcomes and achievements to Genome Canada within describing reports final submit to required are leaders in ended projects 2007–08; the the remainder concluded in of 2008–09. Project in majority the (launched 2003–04), competition strategic first Canada’s Genome through funded projects large-scale 14 the Of (Ongoing) Review Interim Projects III Competition in Human Health Competition Applied Genomics and Proteomics Research tive approaches and avenues to strengthen the projects. alterna regarding advice provide to used also is review The project. the of aspects management and financial the that the and/or economicbenefits are realized;andv) social ensuring towards progress iv) or proposed); (made direction research in changes iii) date; to progress the on based objectives, approved to the achieve ability team’s research the ii) progress; research i) evaluate to was review the of purpose The experts. of panel review international an by III Competition in projects funded 33 all of review interim an undertook 3 LS. Projects are selected for funding through a rigorous scientific peer-review process involving international experts, together industry, governments, universities, research hospitals and the public. The support of large-scale projects of strategic importance to Canada, Objective 3: by bringing —In September 2007, Genome Canada Canada Genome 2007, September —In (Completed) Performance for2008–09 3 LS issues and potential socio-economic benefits related to genomics to related benefits socio-economic potential and issues LS — - (does not merit funding). Applicants received the results non-competitive or competitive were proposals whether the International Review Committee in order to determine scientific review of each proposal by several members of subjected to a streamlining process which involved a full a result of high application pressure, the proposals were Canada had received 48 full proposals. In November,Genome as 3, October By competition. the of scope the and guidelines the clarify to regions six the of each in conducted information sessions with potential applicants Canada Genome June, of month the During 20. May by received were Intent of Letters 58 of total A criteria. evaluation and guidelines competition the of release the and Applications for Request a with 2008, 1, April agriculture crops, bioenergy and bioproducts was launched competition on applied genomics research in the areas of or Crops Competition Applied Genomics Research in Bioproducts final yearin2009. Competition III projects will be entering their fourth and science review committee were resolved. The majority of international the by identified issues all that ensure to 2008–09 through continued projects all of monitoring were subject to a site visit. The ongoing management and respond to the issues identified by the review panel and 3 were approved to proceed as proposed, 13 were required to the interim review, 17 projects required no follow-up and should be continued, reduced or cancelled. As a result of project a for funding whether determine will review The (Ongoing) —A strategic

up totwoyears. take can Directors of Board the by funding for approval to Intent of Letter a of submission the from process full process as well as diligence international scientific peer due review. The rigorous a to submitted is proposal The bring together key stakeholders to develop a full proposal. met, funding is provided for an international workshop to are criteria ICI the if and, Committee Advisory and Industry Science Canada's Genome by reviewed are which Canada, Genome to Intent of Letters submit Applicants the international status of Canada and Canadian scientists. enhance further will which researcher(s), Canadian a by genomics scientific research project (more than $50M) led An International Consortium Initiative (ICI) is a large-scale Initiatives International Consortium and EvaluationStrategy. Performance,Audit Canada’s Genome of implementation the final reports will be developed as part of the on-going three months of completion. The process for the review of the outcomes and achievements to Genome Canada within leaders are also required to submit final reports describing competition bilateral project Their 2007–08. in ended 2003–04) in (launched international Genome first through Canada’s funded projects large-scale Three (Completed)— Plants andAquacultureCompetition España JointProjectsinHumanHealth, Genome Canada–Genoma INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– the Genome Canada Board of Directors in 2009. February by discussed were Committee Review International the of recommendations the after notified were competition ABC the of applicants successful Twelve 2009. 18–21, January on Toronto in Committee Review International the of members with meeting face-to-face a to invited were range competitive the in deemed proposals those of during the first week of December 2008, and the applicants SECTION 1I – Pursuing our Objectives:

• ment includethe: Current ICIs either funded in 2008–09 or under develop the consortia. of meetings Committee Steering Management and Board, Committee Advisory Scientific Directors, of Board International the in participation through oversight ongoing in involved is Canada Genome ICIs, proposalsthe with appropriate of expert input. review For the funded the conduct and proposals full the of partners support the applicants during the development For those ICIs under development, Genome Canada and Structural Genomics Consortium (SGC) Consortium Genomics Structural determine thestructureofmembrane proteins. to bear to brought be could that resources the in increase an to lead may that consortium the for partners potential with discussions collaborative strategic as well as workshops, and symposiums including activities outreach Cell, and Nature as such publications science in papers seminal of number a of publication the structures, protein 48 to up of determination the include 2008–09 several including in Activities proteins. membrane integral human proteins, 600 another of II, the SGC will generate and release the structures comprising the consortium was approved. In Phase funding for Phase II (2007–11) by the stakeholders I (2003–07) by an international review committee, new drugs. Following a successful review of Phase protein these structures willof greatly facilitate the development availability of The restriction. without domain public the in them place and malaria) causes that parasite the from proteins example, (for relevance medical of proteins of structures three-dimensional the determine to mandate a with consortium international profit

(Ongoing) Performance for 2008–09 —The SGC is a not-for- a is SGC —The -

17 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 16 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I–Pursuing ourObjectives: 3 to Genome Canada’s strategy is ensuring that the GE the that ensuring is strategy Canada’s Genome to as well as a due diligence process that examines the excellence of the proposals’ financial and management elements. Central and GE technologies, forestry,new environment, fisheries, agriculture, health, of areas the in proposals for calls issue to is funded are calibre highest the of projects research proteomics and genomics large-scale that ensure to strategy Canada’s Genome Strategy forsuccess and proteomicsresearchareaddressedasanintegratedcomponentofeachproposal. What wasachieved NATIONAL STRATEGIC RESEARCHPRIORITIES– and EvaluationStrategy. implementation of Genome Canada’s Performance, Audit the final reports will be developed as part of the on-going three months of completion. The process for the review of the outcomes and achievements to Genome Canada within describing reports final submit to required are leaders in ended projects 2007–08; the the remainder concluded in of 2008–09. Project in majority the (launched 2003–04), competition strategic first Canada’s Genome through funded projects large-scale 14 the Of (Ongoing) Review Interim Projects III Competition in Human Health Competition Applied Genomics and Proteomics Research tive approaches and avenues to strengthen the projects. alterna regarding advice provide to used also is review The project. the of aspects management and financial the that the and/or economicbenefits are realized;andv) social ensuring towards progress iv) or proposed); (made direction research in changes iii) date; to progress the on based objectives, approved to the achieve ability team’s research the ii) progress; research i) evaluate to was review the of purpose The experts. of panel review international an by III Competition in projects funded 33 all of review interim an undertook 3 LS. Projects are selected for funding through a rigorous scientific peer-review process involving international experts, together industry, governments, universities, research hospitals and the public. The support of large-scale projects of strategic importance to Canada, Objective 3: by bringing —In September 2007, Genome Canada Canada Genome 2007, September —In (Completed) Performance for2008–09 3 LS issues and potential socio-economic benefits related to genomics to related benefits socio-economic potential and issues LS — - (does not merit funding). Applicants received the results non-competitive or competitive were proposals whether the International Review Committee in order to determine scientific review of each proposal by several members of subjected to a streamlining process which involved a full a result of high application pressure, the proposals were Canada had received 48 full proposals. In November,Genome as 3, October By competition. the of scope the and guidelines the clarify to regions six the of each in conducted information sessions with potential applicants Canada Genome June, of month the During 20. May by received were Intent of Letters 58 of total A criteria. evaluation and guidelines competition the of release the and Applications for Request a with 2008, 1, April agriculture crops, bioenergy and bioproducts was launched competition on applied genomics research in the areas of or Crops Competition Applied Genomics Research in Bioproducts final yearin2009. Competition III projects will be entering their fourth and science review committee were resolved. The majority of international the by identified issues all that ensure to 2008–09 through continued projects all of monitoring were subject to a site visit. The ongoing management and respond to the issues identified by the review panel and 3 were approved to proceed as proposed, 13 were required to the interim review, 17 projects required no follow-up and should be continued, reduced or cancelled. As a result of project a for funding whether determine will review The (Ongoing) —A strategic

up totwoyears. take can Directors of Board the by funding for approval to Intent of Letter a of submission the from process full process as well as diligence international scientific peer due review. The rigorous a to submitted is proposal The bring together key stakeholders to develop a full proposal. met, funding is provided for an international workshop to are criteria ICI the if and, Committee Advisory and Industry Science Canada's Genome by reviewed are which Canada, Genome to Intent of Letters submit Applicants the international status of Canada and Canadian scientists. enhance further will which researcher(s), Canadian a by genomics scientific research project (more than $50M) led An International Consortium Initiative (ICI) is a large-scale Initiatives International Consortium and EvaluationStrategy. Performance,Audit Canada’s Genome of implementation the final reports will be developed as part of the on-going three months of completion. The process for the review of the outcomes and achievements to Genome Canada within leaders are also required to submit final reports describing competition bilateral project Their 2007–08. in ended 2003–04) in (launched international Genome first through Canada’s funded projects large-scale Three (Completed)— Plants andAquacultureCompetition España JointProjectsinHumanHealth, Genome Canada–Genoma INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– the Genome Canada Board of Directors in 2009. February by discussed were Committee Review International the of recommendations the after notified were competition ABC the of applicants successful Twelve 2009. 18–21, January on Toronto in Committee Review International the of members with meeting face-to-face a to invited were range competitive the in deemed proposals those of during the first week of December 2008, and the applicants SECTION 1I – Pursuing our Objectives:

• ment includethe: Current ICIs either funded in 2008–09 or under develop the consortia. of meetings Committee Steering Management and Board, Committee Advisory Scientific Directors, of Board International the in participation through oversight ongoing in involved is Canada Genome ICIs, proposalsthe with appropriate of expert input. review For the funded the conduct and proposals full the of partners support the applicants during the development For those ICIs under development, Genome Canada and Structural Genomics Consortium (SGC) Consortium Genomics Structural determine thestructureofmembrane proteins. to bear to brought be could that resources the in increase an to lead may that consortium the for partners potential with discussions collaborative strategic as well as workshops, and symposiums including activities outreach Cell, and Nature as such publications science in papers seminal of number a of publication the structures, protein 48 to up of determination the include 2008–09 several including in Activities proteins. membrane integral human proteins, 600 another of II, the SGC will generate and release the structures comprising the consortium was approved. In Phase funding for Phase II (2007–11) by the stakeholders I (2003–07) by an international review committee, new drugs. Following a successful review of Phase protein these structures willof greatly facilitate the development availability of The restriction. without domain public the in them place and malaria) causes that parasite the from proteins example, (for relevance medical of proteins of structures three-dimensional the determine to mandate a with consortium international profit

(Ongoing) Performance for 2008–09 —The SGC is a not-for- a is SGC —The -

17 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 18 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: • • initial fundingoftheconsortium. the since made progress the and leaders project the of expertise the timeliness, its ICI, the by undertaken being work the of importance the acknowledged and ICI the for support continued recommended reviewers research team’s ability to achieve future objectives. The the and date to progress evaluate to Montreal, in assess progress against scientific and to was review the of purpose The Toronto. in 2009, 29, January undertaken was review interim An ICI. the of development staged the for funding of year one approved Canada Genome of Directors of Board the 2007, June In development. of stages and tissues different in factors transcription 570 for genes target and proteins interacting identify to are objectives consortium’s the model, primary the as mouse the using and tools genomics and proteomics Employing medicine. regenerative and research cell stem for mammalian cells during development, with implications in regulated is function gene how exploring of goal overarching the with consortium international profit cohort and founding member of P of member founding and cohort population-based a biobank, CARTaGENE the is ICI health and well-being. A key component of the P the of component key A well-being. and health public improve to knowledge new generate will and disease and health to contributions environmental and genetic the of studies needed for numbers sample large the provide will harmonization This biobanks. international different from collected data and of P of goal The (biobanking). genomics population of field the in projects and researchers between collaboration fostering of aim the with consortium international (P Genomics in Project Population Public (Under Development) (Under International Regulome Consortium (IRC) of the P the of 50,000 Quebec citizens aged 40–69. An interim review from samples DNA and material biological and data, assessment health and socio-demographic collect 3 G) 3 G is to facilitate the harmonization of samples of harmonization the facilitate to is G (Ongoing) 3 G ICI was undertaken on April 23, 2008, 23, April on undertaken was ICI G —P 3 —The IRC is a not-for- a is IRC —The G is a not-for-profit a is G GE 3 G that aims to aims that G 3 LS milestones

Performance for 2008–09 3 G • (Under Development) (Under The International Barcode of Life (iBOL) funding support. new of Canada Genome by receipt the and impact, socio-economic and scientific global and national of the scientific merits of the IRC and its potential for of Directors' assessment at its March 2009 meeting successful outcome of the interim review, the Board contingent upon a number of factors, including the remaining four years of the consortium’s activities is the for support funding Future deliverables. and 2009–10. impact, approved funding support for the iBOL for socio-economic and scientific global for potential conservation biologists and many others and has the that the research will be of great value to scientists, 2009 meeting, the Board of Directors, recognizing February its At support. funding new of Canada ICI for six years contingent upon receipt by Genome Review Committee's recommendation to support the the with meeting, 2008 December its at agreed, Directors of Board Canada Genome The Toronto. in 2008, 7, November on experts of committee international an by reviewed was proposal ICI iBOL The partners. funding potential engaging and structures management and governance appropriate developing included this proposal; ICI an of development facilitate to stakeholders key project leaders, Ontario Genomics Institute staff and In 2007–08, Genome Canada worked with the iBOL III. Competition of aegis the under partners and Barcode of Life Network funded by Genome Canada Canadian the of accomplishments technical the on builds Consortium iBOL The years. five within importance socio-economic of species 500,000 over catalogue would which effort, identification species worldwide a initiate to “barcoding” DNA use will that consortium international for-profit —The iBOL is a not- a is iBOL —The

PLATFORM/SERVICES PROVIDED Training • Help Desk • Software Tools • Bioinformatics Platform(Calgary DNA sequencing • Proteomics • Functional Genomics • Genotyping • Innovation Centre McGill UniversityandGenomeQuebec Biobanking • Statistical Analysis • Genetic Analysis • Cytogenomics andGenomeResources • Microarray AnalysisandGeneExpression • DNA SequencingandSynthesis • The CentreforAppliedGenomics(Toronto) Proteomics • University ofVictoriaProteomics Centre Bioinformatics • Gene expressionprofiling • Clone fingerprintmapping • • DNA sequencing Sciences Centre British ColumbiaCancerAgencyGenome Microarray Analysis • Vancouver GeneralHospital (not includingBioinformatics Platform) • Statisticsformostoftheplatformsare basedonaone-yearperiodfrom2007to2008 Notes: TOTAL Table 1-ScienceandTechnology PlatformsUserStatistics SECTION 1I – Pursuing our Objectives: )

Non-Genome Canadarequests Non-Genome Genome Canadaprojectsrequests Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Industry CanadaAcademic Non-Genome Genome Canadaprojects Non-Genome CanadaAcademic Non-Genome Genome Canadaprojects USERTYPE

Performance for 2008–09 (as atNov. 2008) Total Total Total Total Total Total

120 579 567 996 OF CLIENTS NUMBER 1329 646 350 538 543 113 29 26 63 37 70 30 12 13 11 – 4 7 3 3 1

15 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 14 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: January 2010. January for scheduled is workshop next The services. technology high-quality delivering in practices and methods best share to and communication, cross-platform improve to methods discuss to platforms, the by available made day workshop to share details of advances in technologies from the Genome Centres met in January 2009 for a two- members staff and platforms, of representatives other The leaders of the six Genome Canada-funded platforms, Meeting (Ongoing) Leaders TechnologyPlatform and Science Technology platformsuntilMarch31,2011. and Science six funded currently the for support extend Science and Technology Operations Support, but rather to February for Competition the with proceed its not to meeting, 2009 at agreed, Directors of Board Genome The Canada Competition. Crops or Bioproducts in Research Genomics Applied the from projects pending and projects, III Competition Canada Genome ongoing for support operations, platform S&T for applications Performance for 2008–09 4 • activities: GE national its refine and advance to continued Canada Genome 2008–09, In What wasachieved GE large-scale of support the including elements, various of composed is research proteomics and genomics to related issues Genome Canada’s strategy to ensure Canadian leadership in the areas of ethical, environmental, economic, legal and social Strategy forsuccess credibility andawareness. visibility,establishing at aimed programs outreach public and education innovative develop to is public Canadian the to research proteomics and genomics of successes and rewards risks, relative the communicate to strategy Canada’s Genome Canada-funded projects. 3 LS research projects having national and international impact, and the integration of that that “Difference the on focused participants symposium Genome Canada community and beyond. Finally, the the for agendas research future influence to likely research and explored new trends and opportunities GE In April 2008,Genome Canada hosted an International International GE Participants discussed contemporary issues in GE apply to seek they when have stakeholders various theme of knowledge translation and the expectations benefits therefrom. GE reconnected to tour the abroad and Canada from Researchers Landscape. (Completed) 3 3 3 LS Symposium entitled Navigating the Changing the Navigating entitled Symposium LS LS GE research results in practice and derive concrete research results from around the world. world. the around from results research the Canadianpublic. communication of the relative risks, rewards and successes of genomics to legal, social and other issues related to genomics research (GE The assumption of leadership in the area of ethical, environmental, economic, Objective 4: 3 LS Makes” by exploring the burgeoning burgeoning the exploring by Makes” 3 LS framework with the following following the with framework LS SECTION 1I – Pursuing our Objectives: 3 LS Symposium GE 3 LS landscape and present GE 3 LS •

• d’être.” researchers, technology users, policy-makers an on continue will Work public. general the policy-makers and users, technology researchers, tangible outcomes for relevant audiences, including concrete, into results research translate to efforts systematic and dedicated encouraging also while national strategy for taking National GE Development and Implementation of a GE Recruitment of a Chief GE Chief a of Recruitment In December 2008, Genome Canada supported a supported Canada Genome 2008, December In Chief full-time new, a created Canada Genome the next generation of implementation of a national strategy that defines initiate and develop to mandated been has Officer (Completed) the integral importance of and area this to commitment ongoing and serious Canada. This new position signals Genome Canada’s 2008 for a two-year period. The new Chief new The period. two-year a for 2008 several months, the position was filled in of September process recruitment a After organization. the to continue to support world-class GE world-class support to continue to next level. The overarching theme of this strategy is 3 Officer position to join the senior ranks of ranks senior the join to position Officer LS Performance for 2008–09 3 LS Strategy(Ongoing) GE 3 LS aspects in all other Genome GE 3 LS leadership at Genome GE GE 3 LS to its very “raison 3 LS 3 leadership to the LS), and the 3 LS Officer Officer LS 3 LS research LS GE 3 LS

19 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 20 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I–Pursuing ourObjectives: • •

(Ongoing) which include: strategy this of components various the implement ongoing basis over the next two years and beyond to New GE New and networking across the broader GE consultation, and promote a virtual space for dialogue and input for vehicle a manner,as timely a serve in information relevant exchange to launched be will In Spring 2009, a new GE new a 2009, Spring In GE in Canada. Work on developing and maintaining the policy-makers, themediaandgeneralpublic. researchers, for resource informational meaningful • • • • delivered toallaudiences. regional basis to ensure that a consistent message is a on tools and activities these using or developing, managing in collaborators been have Centres partners and other key stakeholders. The six Genome government policy and decision-makers, researchers, parliamentarians, media, public, the to targeted are initiatives These tools. and activities outreach public and communications unique and innovative implemented and developed has Canada Genome research, proteomics and issues genomics surrounding important the understand to Canadians assisting of objective national its to response In Education and Public Outreach • • • 3 LS webpage will continue in order to provide a provide to order in continue will webpage LS supporting measuring andevaluating strengthening the showcasing Canadian research resultsintoaction enabling a vibrant international stage bringing GE bridging the 3 LS Webpage at Genome Canada Genome at Webpage LS 3 GE LS research results GE 3 LS 3 LS research-publicpolicygap researcherstotranslate GE GE 3 3 LS integrationmodel GE LS network across Canada 3 LS @ Genome webpage Genome @ LS 3 LS GE researchonthe 3 home LS success 3 LS community to Canadians (Ongoing) Performance for2008–09 • •

, during the 200 the during 2008, 18, June On projects. in Genome(seebelow). GEEE! The exhibition the to pertaining press conference another organized also Canada Genome Consortium. Cell Stem Cancer the of creation the announcing California from representatives and Health, of Minister TonyClement, Honourable the Canada participated in a joint press conference with Diego Biotechnology development technology 13 in investment $9.37M a announce to Industry, of Minister the of behalf on Ablonczy, Diane Honourable the Tourism, and Business Small of Minister the with conference 30, 2009. will welcome the exhibition from January 15 to April Mines Thetford de minier et minéralogique Musée for the summer and to Thunder Bay for the fall. Le Deer Red to on moved then exhibition Genome in exhibition in the history of the Museum. The GEEE! visited most third the was exhibition The Science. of World Edmonton TELUS the at media, the by attended ceremony, official an during exhibition the opened Diversification) Economic Western of (Minister of Intergovernmental Affairs and Minister 2008 in Edmonton. The Honourable Rona Ambrose second three-year cross-Canada tour on March 19, 2500-sq-ft bilingual travelling exhibition, started a The GEEE!InGenome media coverage. by the national and international media for broad releases in fiscal year 2008–09 that were picked up News Releases and News Conference On May 5, 2008, Genome Canada held a news news a held Canada Genome 2008, 5, May On The GEEE! in Genome, a refurbished and updated and refurbished a Genome, in GEEE! The press six issued partners and Canada Genome Industry Industry Conference, Genome 8 San 2 manage andmonitornew, large-scaleresearchopportunities,andassistinfundraisingactivities. and genomics- all in proteomics-related areas, the researchers Centres facilitate access For to leading-edge Genome projects. Canada fully funded research S&T platforms, identify, proteomics and genomics large-scale manage and in co-invest that organizations not-for-profit are Centres Genome These Canada. across region each in Centres Genome support to is Genome Canada’s strategy to ensure effective management and monitoring of its funded research projects and S&T platforms Strategy forsuccess What wasachieved Genome Centres addition of a separate allocation of funding for the the for funding of management ofprojects. allocation separate a of addition the with along Centre, each of expenses administrative general support to funding of amount base new a reflect to model funding the to adjustment an included Results Centres’ the abilities to deliver on their disrupting individual funding agreements. without efficiencies gain and services improve to ways determining as well as funding delivery service current of review a included discussions These model. funding Centre Genome the re-examine to between Genome Canada and the Genome discussions Centres were undertaken 2007–08, In framework. policy national a within operate to Centre each for provisions necessary the provides also but Centre, Genome each of independence the acknowledges that agreement funding a of means by managed is Centres Genome the of each and Canada Genome between relationship business The GenomeAtlantic(Halifax) • GenomeQuebec(Montreal) • OntarioGenomicsInstitute(Toronto) • GenomePrairie (Saskatoon,withasatellite • GenomeAlberta(Calgary) • GenomeBritishColumbia(Vancouver) • Centres, whicharelocatedacrossCanadaasfollows: Genome Canadasupportstheoperationsofsix office inWinnipeg) and theAtlantic. are there which of currently six, one each Canada, in British Columbia, Alberta, the across Prairies, Ontario, Quebec Centres Genome regional through fields The provision of leading-edge technology to researchers in all genomics-related Objective 2:

(Ongoing) SECTION 1I – Pursuing our Objectives:

February 6, 2009. The purpose of this RFA is to solicit solicit to is RFA this of purpose The 2009. 6, February on Canada Genome at due Intent of Letters with Support Operations Technology & Science an for of competition launch open the approved also Board The platforms. S&T currently-funded the for funding interim of year one In June 2008, Genome Canada’s Board of Directors approved (Ongoing) Operations Support Technology and Science for Competition be availableinthelatterhalfof2010. will results their and 2008 July by launched were projects Development Technology 13 All Canada. across platforms Canadian scientific community and the already-funded S&T and update the menu of technologies available to the entire broaden will projects research these from outcomes The 2007. December in Directors of Board the by accepted was which $9.5M), is contribution Canada’s Genome which (of 51 proposals for two years at a cost of approximately $19M Scientific Review Committee recommended funding 13 of the to improve production of large-scale data. An International large datasets, entirely new technologies, and in-lab devices analyzing for and software new genomics instrumentation, of proteomics generation latest the for techniques new processes, existing to improvements such incremental as development, technology of aspects various with deal that proposals solicit to was intent Its 2007. April in launched was Competition Development Technology The (Ongoing) Technology DevelopmentCompetition

Performance for 2008–09

GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 13 12 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: • •

not playanactiveroleintheseactivities. approach. Genome Canada determined that it would step to demonstrate the feasibility and utility of this developed and implemented a pilot project as a first scientists of group small a workshop, the Following of the cost/benefit analysis of the various approaches. value and utility; it would also enable an assessment them and assessing which leads would be of greatest human characterizing for of way leads agreed-upon proteins—an new validate and identify to mechanism a of establishment the for allow would consortium The proteins. human for probes specific and selective develop to consortium international an creating of possibility the explore to Sweden, A workshop was held March 15, 2008, in Stockholm, international genomicsresearchcommunity. the by used be to data of types specific for practice and to produce guidelines for what this will mean in recommendations to encourage rapid release of data developing on focus will 2009, Spring for planned workshop, The workshop. release data international an of development the leading is Canada Genome Forum, Funders' International the of aegis Under Data ReleaseWorkshop(New) Protein Ligand Workshop (Completed) —

Performance for 2008–09 — • • • • international genomics andproteomicsconferences: following the at presence the followingyoutheducationprograms: Genome Canada showed its support or or support its showed Canada Genome Conference Support In 2008–09, Genome Canada partnered with Programs Partnering withYouth Education • • • • • • • • • the Sanofi–Aventis BiotechChallenge, the Canada-wideScienceFair, which Spring 2008. the country, May2008; best scienceprojectsfromacross attracts high-schoolstudentswiththe Summer 2008 Pharmacology andTherapeutics, The IXthWorld ConferenceonClinical Summer 2008 Amsterdam, Fall2008 India, Fall2008 HUGO (HumanGenomeOrganization), Diego, Spring2008 biotechnology conference),San BIO (thelargestinternational Université LavalCongrésIUFRO, BioContact, QuebecCity, Fall2008 HUPO (Human Toronto,Bio-Finance, Spring2008 SECTION 1I – Pursuing our Objectives: Proteome Organization) ,

• to itsdiverseclientele. trends in this field, but also offers better service It not only responds better to current needs and ever financial database and a search capability. spring of 2008. The new website includes a first- Canada the in website new a Genome launched and developed website, its of look and In order to improve the content, navigability content, the improve to order In Website

Performance for 2008–09

21 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 22 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: 5 Strategy forsuccess from abroad. and Canada within from contributions for commitments researchers, the and Centres Genome the through and/or itself is to continue developing collaborative relationships with the private, public and philanthropic sectors as well as to secure, by others. Genome Canada’s strategy to encourage investment by others in excellent large-scale genomics research projects Genome Canada funds up to 50% of the eligible costs of research projects, with the remainder secured through co-funding funders asshowninthefigurebelow. co- with funded jointly being are and have which $1.5B totaling projects approved has Canada Genome 2000, Since What wasachieved Note: INSTITUTIONAL The encouragement of investment by other Persons in the field field the in Persons other by of Genomicsresearch. investment of encouragement The Objective 5: FUNDING SOURCESFOR Figure above does not include funding and related co-funding ofGenome Centres. Figure abovedoesnotincludefunding andrelatedco-funding 5% FEDERAL 7% INDUSTRY

10% GENOME CANADA GENOME CANADA 44%

Performance for 2008–09 PROVINCIAL 13% -APPROVED PROJECTS FOREIGN 21%

• Canada and DFO organized a workshop in Ottawa in workshop a organized DFO and Canada been extended to include Norway and has Chile. Genome that proposal a Spain, with aquaculture and joint international initiatives in the area of genomics possible explore to (DFO) Oceans and Fisheries of Canada initiated a collaboration with the Department addressing aquaticanimalhealth. proteomics and genomics in program bilateral a develop to and Chile with DFO working are result, Canada Genome a As time. this at Canada with initiative international joint large-scale a pursue to had Spain the nor interest Norway nor the resources neither that clear was it workshop, as the of result a researchers Chilean and Norwegian Spanish, and community research Canadian the of members between developed collaborations individual some and to determine a mechanism to achieve this. While research genomics collaborative international from key identify questions in to aquatic animal health were that would benefit objectives Their Chile. and Health” Animal Norway Spain, Canada, from participants involving Aquatic Improve “Applied to on Genomics workshop international an hosted co- DFO and Canada Genome 2008, 25–27, June on Barcelona In needs. and opportunities Canadian Canadian define to together industry aquaculture bring the and to scientists 2008, 1, May on Udr development) (Under Canada–Chile Partnership Canada–Chile Partnership Intent in February 2009. Intent inFebruary of Letters of receipt the was competition a such of development the in step first The available. is joint competition which proposed will be launched if a future funding for staff guidelines developed CNR have and Canada Genome strengths. and interests identified common, of areas several projects in research joint support to developed be should Applications for Request joint a that agreed SECTION 1I – Pursuing our Objectives: I 20, Genome 2007, —In

ainl n itrainl okhp, ofrne and symposia, includingthe: conferences workshops, international and national Genome Canada continued to organize, host and co-sponsor Conferences andSymposia National andInternationalWorkshops, • • over thenextdecadeandbeyond. research genomics of future the and diseases childhood of role the government science advisors, stem cells, the genomics of discovery, drug and commercialization variation, genetic human to related topics and on presenters speakers keynote featured than and more participants 225 attracted conference third and This society law. the ethics, economy, the to environment, relates it the how on but bioscience, of world the on just not have, will work this impact the and research genomics in trends future on focused theme conference Vancouver.The in 2008, 22–24, October on on Society— Science of Impact The Vision: conference—2020 international Canadian third its held Canada Genome and the impact of current GE current of impact the and issues highlights, on focused Discussions landscape. Making aDifference. of the closing session entitled Knowledge Translation— website (www.genomecanada.ca), together with a report Canada’s Genome on available publicly are symposium the from posters and abstracts conference biographies, Presenters’ sessions. poster the and presentations oral the both during research discussions the of in engaged number trainees, significant a including the across globe, from participants 150 Over beyond. and community Canada Genome the in agendas research changing drive to likely opportunities and needs new nentoa G³S ypsu 2008 Symposium (Completed) GE³LS International Conference (Completed) Canada Genome International 3rd event offered a comprehensive overview of the GE the of overview comprehensive a offered event three-day The 2008. 28–30, April on Calgary in place Landscape—took Changing the 2008—Navigating

Performance for 2008–09 —The International GE³LS Symposium 3 LS research, as well as well as research, LS —

3 LS GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 11 10 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I – Pursuing our Objectives: June 2008. The CSCC Board is currently developing currently is Board CSCC The 2008. June in organizations two the by signed Understanding of Memorandum the from resulting initiative first the is This research. cell stem cancer on focusing scientists Californian and Canadian of Teams Disease support to Medicine Regenerative for Institute California the and CSCC the by issued was applications for call joint a 2009, February In grants. investigator-initiated individual through feasible not approach large-scale goals that can best be achieved by using an integrated with teams research of development the encourage to applications for requests coordinate members jointly will CSCC The research. cell stem cancer to related issues social and legal ethical, address that those including disciplines, of range wide a across adopt, as a fundamental principle, open collaboration and approaches diverse of development the embrace pursuing common research goals. The and Consortium will platforms technology cutting-edge sharing by biology CSC in advances basic to data clinical patient link to teams research enable will efforts large-scale of support The applications. clinical into findings research translate to and study for CSCs live provide to developed be will infrastructure State-of-the-art on identifying CSC biomarkers and anti-CSC therapies. focus will CSCC the of programs research The years. it will undertake to achieve its goals over the next five activities research of sequence the defines it as CSCC and Californian scientists, will guide the Board of the CSCC Strategic Plan, developed by The a team of Canadian research. cell stem cancer support to contribute funding and consortium the join cancer to companies non-governmental organizations and pharmaceutical and biotechnology agencies, funding provincial and federal as such entities private and in the development of the consortium, inviting public role lead enduring a playing is Canada Genome offer cures. cancer potentially will eradication their and metastases, and growth tumour for accounting cancers, many its of root the at culprits major the be to and research cell considered are (CSC) cells stem stem Cancer applications. cancer on focus to

Performance for 2008–09 • •

Consortium. the of members potential other identifying as well as plan, strategic its of components other implement to (2009–2014) Plan Operational its o adtoa Cnda priiain n the in consortium. participation Canadian additional for opportunities exploring also is Canada Genome funders, Canadian other with Along Committees. Planning Science and Executive the both through consortium the of development the in role active an played have staff Canada Genome ICGC, the States. in status United observer has Canada Genome Although the and Kingdom, United the Spain, Singapore, Japan, India, France, China, Australia,Canada, Countries include ICGC the cancer. in involved in abnormalities genome (somatic) of atlas was an produce to is consortium (ICGC) the of goal The Consortium 2008. April in launched formally Genome Cancer Canada–Italy Partnership Canada–Italy International Cancer Genome Consortium (Under development) (Under (Under development) (Under future collaboration. The workshop participants workshop The collaboration. future to human health and to opportunities identify for related research proteomics and genomics scale activities in Canada and Italy in the area of research large- current of awareness increase to was workshop the of objective The 2008. 7–8, April Rome, in workshop a in participated Italy from number equal an and Canada from funders of representatives and scientists 40 approximately a first step in strengthening this new partnership, As health. and human to related research proteomics genomics large-scale of area the in Italy and Canada between framework collaborative a establishing and linkages existing expanding of objectives the with (CNR) Council Research between Genome Canada and the Italian National 2007 of fall the in signed was Understanding of —The International —The —A Memorandum

levels ofgovernmentandfromtheprivatesector. other from funds additional leverage to ability the has also It investment. judicious and careful through government federal the from receives it grants the maximize to flexibility the has Canada Genome organization, not-for-profit,arm’s-length a As Canada. Genome CanadaandIndustry between agreements funding through formalized grants, conditional of form the in come has funding All years. five next the over Canada Genome of requirements cash annual the on based paid be now will funds these policies, government new with accordance In 2008. February of budget federal the from $140M the and 2007 March of budget federal the in announced was that $100M the of exception the with indicated, years the in sum lump one in provided was funding This 2007–08. in $140M and 2006–07 in $100M 2005–06; in $165M 2004–05; in $60M 2003–04; in $75M 2001–02; in $140M 2000–01; in $160M The federal government, through Industry Canada, has approved a total of $840M in funding for Genome Canada since 2000–01; SECTION 1II Research inHumanHealthCompetition. Proteomics and Genomics Applied the in (2003–06) years three to up for approved were that platforms S&T associated and projects funded ($75M) 2003–04 in government federal the from received grant The operations of Genome Canada and five Genome Centres. the funded also grants These (2002–06). years four to up for II, and I Competitions in approved were that platforms S&T and projects research large-scale the funded ($140M) 2001–02 in and government ($160M) 2000–01 federal the from received Grants Source andUseofFunds the outcomeoftheirdeliberations. committees meet quarterly and report to the Board on Both reporting. financial and auditing management, risk controls, internal and accounting of areas the in activities and processes policies, Canada’s Genome overseeing for responsible is Committee Audit The for the prudent investment and management of funds. policy that outlines guidelines, standards and procedures government according to a Board-approved investment federal the from received funds of management and Committee is responsible for overseeing the investment Investment The management. grant to respect with Genome Canada in fulfilling its fiduciary responsibilities Two Board Committees support the Board of Directors of Investment and Management of Funds – GrantManagementfor2008–09 Technology Developmentprojects. Genomics), as well as a competition in 2007–08 for New Consortium Phase I and the Public Population Project in Initiative, funding for two ICIs (the Structural Genomics Sequencing Genome Bovine the España, Genoma and bilateral research competition between Genome Canada a as Genome such initiatives, research other allowed launch to Canada has investment, federal earned the $80M, with over of earnings investment Federal regional six Genome Centres. the and Canada Genome of operations the and platforms S&T for funding continued as well as Consortium, Cell Stem Cancer the through projects research Crops, and Bioproducts in in Genomics Applied competition a fund will in ($140M) 2008 government February federal the by approved grant The through 2009–10. of Genome Canada and the six regional Genome Centres the Structural Genomics Consortium, and the operations projects, the S&T platforms through 2008–09, Phase II of 2007 ($100M) will fund the fourth year of Competition III The grant approved by the federal government in March S&T platformsuntiltheendoffiscalyear2007–08. six of renewal the and years, three for Centres Genome six and Canada Genome of operations the years, three for III Competition in successful were that projects the funded ($165M) 2005–06 in and ($60M) 2004–05 in government federal the from received grants The

23 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 24 GENOME CANADA — Corporate Plan 2009–10 SECTION 1II– 2000 Canada’s financial statements present fairly, in all in fairly, present statements financial Canada’s Genome whether on opinion an express to is objective The standards. auditing Canadian accepted generally within 45 days of each fiscal year-end in accordance with February for review and approval. The audit is conducted in Committee Audit Canada’s Genome to plan audit an 2008–09 are KPMG LLP. Auditors are required to submit audit of its financial statements; the external auditors for Canada selects external auditors to undertake an annual Genome organization, incorporated not-for-profit, a As Annual Audits submission beforereleasingfunds. request draw the of review thorough a conducts Canada Genome sources. other from received co-funding and reports progress scientific expenditures, actual budget, approved the against needs project/platform the assess Centres Genome quarter.The subsequent the for Centre the of needs cash the indicating Canada Genome to request” “draw a submits then It manages. it that estimate cash requirements for each project and platform and date to expenditures review to required is Centre Genome Each platforms. S&T and projects research approved for Centres Genome regional six the through basis quarterly a on funds disburses Canada Genome Cash Management Funding andInvestments FEDERAL BUDGET LAUNCH 2000 $160M GENOME CANADA 2001 Grant Managementfor2008–09 PROJECTS BEGIN COMP I COMP FEDERAL BUDGET $140M 2001 2002 PROJECTS BEGIN COMP II COMP FEDERAL BUDGET 2003 $75M 2003 FEDERAL BUDGET 2004 2004 $60M PROJECTS PROJECTS CANADA/ BEGIN SPAIN PROJECTS PROJECTS BEGIN APPLIED APPLIED HEALTH FEDERAL BUDGET $165M 2005 2005 PROJECTS PROJECTS COMP III COMP BEGIN completed todate. being six of total a with 2008–09 and 2007–08 in undertaken been have projects individual on audits Recipient administered. is research proteomics and genomics which within framework control ment manage the improve to and Canada across audits introduced to bring a common approach to recipient was framework This audit. compliance detailed a undergo will that platforms and projects identify to Centres the enable to developed was tool assessment with the Genome Centres. As part of this exercise, a risk FrameworkAudit Recipient consultation a in mented imple and developed Canada Genome 2006–07, In Recipient Audits in Juneforapproval. Directors of Board the to then and Committee Audit the to presented are findings audit of summary a completion of the audit, the financial statements and Upon corporation. the of flow cash and operations, of results position, financial the respects, material 2006 FEDERAL BUDGET COMP I&II COMP PROJECTS PROJECTS $100M 2007 ENDS 2007 & CANADA/ PROJECTS PROJECTS APPLIED APPLIED FEDERAL HEALTH BUDGET ENDS SPAIN $140M 2008 DEVELOPMENT TECHNOLOGY 2008 PROJECTS BEGIN 2009 BIOFUELS BIOFUELS PROJECTS & CROPS BEGIN 2010 - - PROJECTS PROJECTS COMP III COMP ENDS • collaborations: instances took on a lead role, in the following international some in and participant, active an was Canada Genome International Collaborations INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– received fromthepeerreviewpanel. comments to according revised be or submitted, as ation consider for process the in remain either will years two The remaining five position papers developed over the past round. third this in considered not were health children’s and agriculture–animals agriculture–plants, products, bio as themes research strategic Such 2008. November in launched was PositionPapersexercise for Request third the criteria, selection and guidelines revised by Supported Position Papers 09 cnet o te nrnt ie en developed being site intranet the for content spring 2009; for scheduled workshop, release data the of planning the on focused Discussions agencies. funding respective their of initiatives ongoing and the mandates on briefly presented participants International present. were States United the and Kingdom United the Sweden, Spain, Norway, Netherlands, Italy, the Japan, Germany, Commission, European the Canada, China, from Representatives Vancouver. in 2008, the hosted 21, October Canada on Forum Funders’ Genome International second site. intranet an of establishment the and release, data on workshop a as well as Forum Funders’ International annual an of from the first meeting, which included the organization recommendations the action to mandated committee steering Canada-led Genome a of establishment the was outcomes the Among City. Quebec in 2007, 16, October on held was forum the of meeting first The collaboration. future for opportunities identify to and projects, these of funding the around issues discuss to projects, genomics international large-scale of funders the among communication and awareness increase to is Forum Funders’ International the of purpose The International Funders’ Forum (Under Development) SECTION 1I – Pursuing our Objectives: (Ongoing)

— - - • • metrics and intellectual property management. evaluation publications, research to access to medium for scientists in Canada and California collaborative a offers directors, of board a by governed is which CSCC, The Canada. Genome and Research, Cancer for Institute the Ontario Network, Cell Stem the Innovation, for Foundation Canadian the Research, Health of the consortium include the Canadian Institutes of Members 2007. November in incorporated formally was (CSCC) Consortium Cancer Cell the Stem agencies, funding and cell experts stem cancer Californian and leading Canadian between meetings and discussions (Ongoing) Consortium Cell Stem Cancer secretariat support. providing Canada Genome with committee steering the of chair as researcher Canadian leading a of appointment the included 2008, meeting that took place IKMC in Toronto on May 13, the of consortium’s Outcomes the committee. steering of member a is Canada Genome mutagenesis. mouse of area the in collaboration international coordinating for vehicle a and as serves biology consortium The disease. human into insight provide will out” “knocked genes specific with mice Studying (IKMC). Consortium Mouse Knockout International the constitute that mutagenesis mouse in projects international Texaslarge-scale four the are the Medicine Genomic and of Institute Project American-led Mouse the Knockout Program, Mutagenesis Mouse Project, Conditional European the with Mutagenesis along Mouse Conditional Consortium International KnockoutMouse with support from the from support with h Gnm Cnd-udd ot American North Canada-funded Genome The recherche recherche recherche

Performance for 2008–09 (France); and specific topics related topics specific (France);and Bidn o to er of years two on —Building (Ongoing) Agence nationale de la la de nationale Agence

— GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 9 8 GENOME CANADA — Corporate Plan 2009–10 SECTION 1I mandate andobjectives. its of fulfillment in 2008–09 for accomplishments and activities major Canada’s Genome outlines section This stage. research in Canada of genomics and proteomics research capacity and to affirming Canada’s stature on the world’s genomics and proteomics Since its creation in 2000, Genome Canada has been committed to encouraging, developing, facilitating and financing the expansion 1 a number of specific areas (health, agriculture, environment, forestry, fisheries, new technologies, and GE and technologies, new fisheries, forestry, environment, agriculture, (health, areas specific of number a in Canada is to assume the role of facilitator or leader, bringing together select Canadian and international groups from Genome Canada’s approach for developing and establishing a coordinated strategy for genomics and proteomics research Strategy forsuccess forums, eventsandresearchprojects. international in participation and Canada, in workshops and conferences of hosting engaged the researchers, included with interaction 2008–09 in Activities research. proteomics and genomics of fields the in interests common have What wasachieved NATIONAL STRATEGIC RESEARCHPRIORITIES– and impactsonthesectorordiscipline. outcomes outputs, socio-economic expected the and years, four over required funding total estimated the Canada, in available capacity resources human and infrastructure the abroad, and Canada in science the provide solutions. It must describe the current state of to bear to brought be can tools genomics/proteomics how and tackled, be to problem(s) the of importance of series a in the define must paper position The papers.” “position described be will themes research strategic These Canadians. to importance economic in nationally recognized areas of interest and of socio- themes research strategic to targeted be will funding that states process the of premise fundamental The years. subsequent and 2008 for research proteomics and genomics in investment future of allocation the optimize to approach new Papers—a Position for In 2006–07, Genome Canada launched the first Request Position Papers(Ongoing)— agriculture, environment, forestry andfisheries. health, forestry agriculture, environment, as such areas in leader world a become to genomics Canada for enable to strategy research coordinated a of establishment and development The Objective 1: – Pursuing ourObjectives:

Performance for2008–09 or CropsinApril2008. Competition in Applied Genomics Research in Bioproducts Genome Canada in the 2008 federal budget led tothe launch of a for funding additional of announcement An in Canada’sFuture). Children’s Health (Child Health Genomics: An Investment and Genomics) TerrestrialAnimal and (Aquatic Animals Agriculture– of areas the on focused forward carried be to recommended papers the 2008–09, In Genomics). through Economy Bio-based Future Canada’s (Securing Agriculture–Plants Bioproducts and Canada) Healthy a for Genomics of (Crop themes the addressed papers Industry Canada. In 2007–08, to the recommended submission position budget and portfolio research strategic Genome Canada for inclusion in Genome Canada’s annual of Board the to recommended were papers position two the in Following aninternational summer of2008.peerreview, papers position completed of submission and production the manage to agreed who leaders selected Participating papers. position writing then communities and (EOIs) Interest of Expressions submitting by themes research strategic identify to stakeholders other with join to community scientific the invited Canada Genome 3 LS) which LS) * As at February 2009 * AsatFebruary Closing CashBalance Opening CashBalance Revenue overDisbursements Excess (deficiency)of Total Disbursements OperatingExpenditures ResearchProjects PROGRAM AND OPERATING DISBURSEMENTS InvestmentIncome GovernmentofCanada REVENUES DISBURSEMENTS TODATE SUMMARY OFREVENUESAND DETAILS (inmillionsofdollars)* GenomeCentres(6) GenomeCanada NewTechnology Development C.difficile CompetitionI S&T Platforms Public Population Project inGenomics StructuralGenomicsConsortium BovineGenomeSequencingProject AppliedGenomicsinHumanHealthCompetition CompetitionIII CompetitionII

International RegulomeConsortium Genome Canada-Genoma EspañaCompetition Genome Canada-Genoma International BarcodeofLife

SECTION 1II–GrantManagementfor2008–09

Projects Funded 128 119 10 33 33 14 13 17

3 1 1 1 1 1 1 to 2007–08 ACTUALS 689.2 585.0 2000–01 426.3 104.2 104.2 69.8 88.9 606.7 146.9 105.5 48.0 80.6 40.9 82.5 57.7 16.3 6.0 0.2 4.3 7.7 0.1 1.0

29.5 (56.6) FORECAST 104.2 60.8 88.0 47.6 2008–09 12.0 (0.7) 15.2 31.4 45.1 6.0 9.2 6.3 2.3 2.2 0.1 0.1 4.1 1.9 1.3

CUMULATIVE FORECAST to 2008–09 720.6 673.0 487.1 104.1 47.6 47.6 636.2 150.6 146.2 81.8 84.4 80.6 46.9 59.9 22.6 57.2 6.0 6.6 0.2 4.3 2.3 7.7 0.1

25 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 26 GENOME CANADA — Corporate Plan 2009–10 and global scientific and socio-economic impact,andthereceiptbyGenomeCanadaofnewfunding support. and globalscientificsocio-economic national for potential the of assessments relevance, and merit scientific of assessments reviews, peer international of outcomes Implementation of many of the proposed major research initiatives is contingent upon a number of factors, including the successful future investmentsbereflectiveofpriorities,asdeterminedbytheBoardDirectors,anddelivervaluefortaxpayers’dollars. The following section outlines Genome Canada’s planned activities for 2009–10. These plans align with its strategic approach that activities withrespecttoassessingresultsoftheresearchithasfunded. several undertake will Canada Genome consortia. international with engage actively and ICIs, of development the in assist and met and to areas identify for improvement. Genome Canada will continue to consult broadly with its research community, assess on-going monitoring and interim reviews of its large-scale research projects and S&T platforms in order to ensure milestones are and proteomics research in Canada, aligning its activities to its five national objectives. It will continue to conduct, as required, In 2009–10, Genome Canada will continue to deliver its mandate as the primary funding and information resource for genomics ACTIVITIES ANDEXPECTEDRESULTSPLANNED FOR2009–10 SECTION 1V 1 NATIONAL STRATEGIC RESEARCHPRIORITIES– international initiatives: and support of the following new and ongoing national and in some instances take a leadership role, in the development Genome Canada will continue to be an active participant, and International CollaborationsandInitiatives INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– and isconfidentitwillbeabletoproceedinduecourse. process valuable and important this to committed remains Canada Genome time. this PositionPaperat Processthe of to-date, Genome Canada will not proceed with the third cycle Not withstanding the excellent work and significant progress Position Papers(Underdevelopment) agriculture, environment, forestry andfisheries. forestry agriculture, environment, health, as such areas in leader world a become to Canada enable to research genomics for strategy coordinated a of establishment and development The Objective 1: – Plans for2009–10

Canada–Chile Partnership (Under development) • Canada–Italy Partnership • International • Cancer StemCellConsortium • International • International Funders’ Forum • Polar GenomicsWorkshop (New) • Data ReleaseWorkshop (New) • 4th InternationalGenomeCanadaConference • conferences andsymposia,includinga: workshops, international and national co-sponsor and host organize, to continue will Canada Genome Conferences andSymposia National andInternationalWorkshops, • (Under development) Turning DataintoKnowledgeWorkshop Knockout

Cancer

Mouse

(Under development) Genome (Ongoing) (Ongoing) Consortium

Consortium (New) (Ongoing) (New)

2 1

"Genomicsmeansthestudyofgenesand their functions,namelygenomics,proteomics,genotyping,sequencing, Genome Canada’sF March 30,2008). bioinformatics andotherrelatedfields ofresearch(asperthedefinitionstatedinFunding Agreement signed objectives: The reportingofplansandactivitiesinthiscorporateplanisorganizedaroundGenomeCanada’sfive outlines anticipatedplansandexpectedresultsforthefiscalyear2009–10. Genome Canada’sCorporatePlan2009–10reportsonactivitiesandperformancefor2008–09, ABOUT THISDOCUMENT 3 2 4 5 1 1

unding AgreementsignedMarch31,2008 social and other issues related to genomics research (GE the assumption of leadership in the area of ethical, environmental, economic, legal, together industry, government,universities,researchhospitalsandthepublic; bringing by Canada to importance strategic of projects large-scale of support the each inBritishColumbia,Alberta,thePrairies, Ontario,Quebec,andtheAtlantic; through regional Genome Centres across Canada, of which there are currently six, one the provision of leading-edge technology to researchers in all genomics-related fields andfisheries; environment, forestry agriculture, health, as such areas in leader world a become to Canada enable to the development and establishment of a coordinated strategy for genomics research the encouragementofinvestmentbyothersinfieldgenomicsresearch. of the relative risks, rewards and successes of genomics to the Canadian public; and SECTION 1 – 3 LS), and the communication About GenomeCanada

2 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 7 6 GENOME CANADA — Corporate Plan 2009–10 SECTION 1– who provide expertise in the delivery of specialized services, areusedonanas-neededbasis. ofspecializedservices, who provideexpertiseinthedelivery Consultants, environment. research ever-changinggenomics an to adaptability and response rapid and nimble for allowing Canada maintains a small staff complement and works within an organizational structure that has few management layers thus comfortable working and collaborating with colleagues and associates at provincial, national and international levels. Genome are who expertise of areas specialized and records track solid with players team results-oriented of CEO,cadre a represents The President and CEO reports to the Board of Directors. The management team, which reports directly to the President and VP Communications Communications VP Claudine Renauld Claudine Communications Communications & Public Affairs & Public Coordinator TBD CONSULTANT AboutGenomeCanada Chief Administrative Officer Administrative Chief GENOME CANADA ORGANIZATION Carol Anne Esnard AnneCarol Marc DesmaraisMarc VP Government VP GennyCardin Director, Operations Director, Relations Analyst HélèneMeilleur Administrative Assistant Administrative Administrative Officer Administrative BrigitteVaillant Julie Julie Bernier Corporate Development Corporate Genomics Programs Genomics Director, National Director, Program Manager Program Program Manager Program Barbara Francis Barbara Executive VP Executive KarenDewar Cindy Bell Bell Cindy KateSwan Board Board of Directors President and CEO President Martin Godbout Martin Director, International Director, Genomics Programs Genomics Program Manager Program Genomics Program Genomics Kim Kim Corbett TBD TBD VP Chief Scientific Officer Scientific Chief Program Administrator Program Shannon Mondoux Shannon Michael Michael Morgan Data Data Manager Tech.Development Patricia Kosseim Patricia Kosseim GE ChuckHasel Consultant 3 Chief Chief LS LS Officer Normand Therrien Normand Financial Officer Financial Robert Moreau Robert Guy D’Aloisio Comptroller Finance VP VP JANUARY 2009 JANUARY 2 in delivering high-quality technology services. in deliveringhigh-qualitytechnologyservices. communication, and sharing best methods and practices platforms, discussing methods to improve cross-platform the by made technologies in advances of details sharing of purpose the for platforms Canada-funded Genome six the of leaders the of meeting annual an be will there maximum access and usage of the platforms. In 2009–10, platform leaders, Genome Canada will continue to ensure S&T the and Centres Genome the with collaboration In Platforms Technology (Ongoing) and Science and abstractspresentedatmeetingsconferences. reports, publications, as such outcomes project any of Canada maintains proper financial Genome oversight as that well as awareness ensure will This milestones. to progress describing reports through quarterly projects development technology successful the monitor will Canada Genome Centre, Genome each with Working Projects Development Technology of Management support. oversight of operational and to project respect management with funding 2009–10 in Centres Genome the with Genome Canada will continue to work in close collaboration Genome Centres and theAtlantic. are there which currentlyof six, one each Canada, in British Columbia, across Alberta, the Prairies, Centres Ontario, Quebec, Genome regional through areas The provision of leading-edge technology to researchers in all genomics-related Objective 2: (Ongoing) (Ongoing)

SECTION 1V–Plansfor2009–10

27 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 28 GENOME CANADA — Corporate Plan 2009–10 SECTION 1V– 3 (Under development) child healthatthistime. in research genomics applied on competition strategic a of launch the with proceed not will Canada Genome date, to- progress and work significant the Notwithstanding Competition (Underdevelopment) Health Child in Research Genomics Applied and terrestrialanimalsatthistime. aquatic in research genomics applied on competition tegic Genome Canada will not proceed with the launch of a stra Notwithstanding the significant work and progress to-date, development) Competition Animals Terrestrial and Aquatic in Research Genomics Applied begin. will competition crops and bioproducts the for projects all of oversight and management and released be will Funds or CropsCompetition(Ongoing) Bioproducts in Research Genomics Applied for funding. to emerging opportunities, which may evolve into requests Genome Canada will continue to seek out and be responsive Emerging Issues in 2009–10. receipt of some final reports which are due to be completed the for preparation including III Competition for projects all of monitoring and management ongoing be will There Competition IIIProjects(Ongoing) Genome Canada recognizes the importance of launching, of importance the recognizes Canada Genome However, time. this at research discovery to dedicated Genome Canada will not proceed with an open competition Competition Frontiers Genomics New NATIONAL STRATEGIC RESEARCHPRIORITIES– and thepublic. hospitals research universities, government, industry, together bringing by Canada to importance strategic of projects large-scale of support The Objective 3: Plansfor2009–10 (Ongoing) (Under -

• • • • As for the funded ICIs (SGC and P and (SGC ICIs funded the for As input. expert appropriate with proposals the of review the during the development of the full proposals and will conduct Genome Canada and its partners will support the applicants development, under ICIs those For ICIs. new for Intent of Letters review and accept to continue will Canada Genome Initiatives International Consortium INTERNATIONAL STRATEGIC RESEARCHPRIORITIES– research competitions. applied or strategic include also would which portfolio periodically, open competitions as part of a balanced research activities areplanned: specific following The meetings. Committee Management and Committee Steering Board, Advisory Scientific International Directors, of Board the in participation through oversight on-going the in involved be to continue (Ongoing) development) International Barcode of Life (iBOL) development) (Under (IRC) Consortium Regulome International Public Population Project in Genomics (P (Ongoing) (SGC) Consortium Genomics Structural Advisory Board,andSteeringCommitteemeetings. Advisory Science International Annual, Board, at participation as well as oversight of the activities of the IRC through international peer review committee’s recommendations the of follow-up possible IRC, the of review Directors' Science Advisory Board,andmanagement meetings. Science Advisory through participation in Board, Annual, International ongoing oversight of the activities of the iBOL project. as well as recommendations committee’s review peer protein structuresareontrack. three-dimensional of determination the for stones —oversight of the activities of the P the of activities the of —oversight mile target that ensure to —oversight —follow-up of the international the of —follow-up 3 G), Genome Canada will Canada Genome G), —Pending Board of of Board —Pending

(Under 3 G) G) 3 G - established established Canada’s leadership in GE has Canada Genome history, short relatively its Over • • • • • advisors totheBoardofDirectors. Humanities Research Council—are non-voting, ex-officio and Sciences Social and Council, Research Engineering Research, National Research Council, Natural Sciences and Health of Institutes Canadian Innovation, for Foundation Canada agencies—the research federal major five of Presidents The communities. sector public and private comprising up to 16 individuals drawn from the academic, Directors of Board a by governed is Canada Genome and anannualreport. plan corporate a of submission the of way by Industry of Genome Canada reports to Parliament through the Minister Governance position intothenextphase. leadership its take to Canada Genome for actions and comprehensive a of implementation and development the with area this in effort its consolidating is Canada Genome research. proteomics and genomics with associated implications the World HealthOrganizationcalled“stunning.” allowed the sequencing of the SARS virus, at a speed that one the as such projects, research genomics sophisticated equipment serve numerous large-scale and machines sequencing where Columbia, British creating state-of-the-art facilities such as the one in of developingbiotechnologyinAfrica; benefits the enabling in leadership global providing Newfoundland’s fishingindustry; stress or disease, creating opportunities to revitalize to resistance and growth for responsible genes identify to cod Atlantic the of genome the mapping temperatures, promising a new approach to forestry; higher or drought pests, to resistant more are that trees grow to tools genomics of development world’s mosteconomicallyimportantfruit; the grape, wine the of genomics the into research GE 3 strategy that will identify priorities LS strategy that will identify 3 LS LS and the potential SECTION 1 GOVERNANCE STRUCTURE GENOME CANADA areas ofgenomicsandproteomicsinCanada. integrated strategy for research and development in the an on expertise and advice visionary and strategic and Industry Advisory Committee (SIAC) that provides Science a established also has Directors of Board The and CompensationCommittee. Election Committee, Corporate Governance Committee Committee, Investment Committee, Audit Committee, Executive an including duties, its discharge it help to committees of number a establishing Canada, the stewardship of the business and affairs of Genome for responsibility overall has Directors of Board The COMMITTEE COMPENSATION COMMITTEE INVESTMENT COMMITTEE EXECUTIVE DIRECTORS BOARD OF MEMBERS – AboutGenomeCanada COMMITTEE GOVERNANCE CORPORATE COMMITTEE ELECTION COMMITTEE AUDIT

COMMITTEE ADVISORY INDUSTRY SCIENCE & GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 5 4 GENOME CANADA — Corporate Plan 2009–10 SECTION 1– munity, as reflected in the receipt of large numbers large of receipt the in munity,reflected as has generated much interest from the research com- date to competitions five Canada’s Genome of Each and technology(S&T)platforms. 128 than innovative, large-scale research projects more and science support to $1.9B over total will investment the sectors, philanthropic and public private, the in partners from commitments funding proteomics research. When combined with estimated and genomics to $900M than more of commitment Canada. To date, Genome Canada has planned for the to importance scientific strategic of projects scale research hospitals and the public in support of large- government departments and agencies, universities, industry,together brings Canada Genome partners. international and domestic both with projects of proteomics research in regionsand across Canada and genomics the co-funding in expertise of points focal of fostering the includes technology also It and platforms. science and projects peer-reviewed research international multidisciplinary, and large-scale managing and funding of premise the on based is model business Canada’s Genome these andotherissues. on Canadians with communicating to and research, and social (GE social and with regard to ethical, environmental, economic, legal role leadership a assuming to committed is Canada Genome well, As development. technology new and fisheries forestry, environment, agriculture, health, benefit of all Canadians in key selected areas such as strategy in genomics and proteomics research for the national implementa develop and to mandateis Its research. proteomics and genomics in leader world a as Canada position to is vision Canada’s Genome to genomicsandproteomicsresearchinCanada. relating resource information fundingand primary the is It Canada. Industry agreement with funding a through formalized is government the to link Its Ontario. Ottawa, in office head its with 2000, February in created was Canada Genome government. federal the from length arm’s at corporation, not-for-profit a is Canada Genome 3 ) issues associated with genomics with associated issues LS)

About GenomeCanada • projects haveledto: Canada-funded Genome example, For community. benefits not only for Canadians, but alsosocio-economic for thehave global will that projects innovative launching in lead the taken has Canada Genome research priorities. proteomics and genomics international of strategic identification the in leadership and expertise contributing is Canada Genome collaborations, multilateral and bilateral developing to workshops and symposia international in participating funding and from ranging activities proteomics Through and arena. genomics international the in player major a as recognized is Canada Genome for regionalpublicoutreachprograms. opportunities create Centres Genome the thermore, Fur fundraising. and management development, project to approaches different applying in assist and platforms, S&T leading-edge to access facilitate Centres Genome the areas, proteomics-related and proteomics research. For researchers in all genomics- tions that support, at a regional level, genomics and organiza not-for-profit are Centres Genome These Montreal, Toronto, Saskatoon, Calgary and Vancouver. Six Canadian Genome Centres are located in Halifax, outstanding internationalresearchcollaborations. ties for Canada’s scientists to develop skills and lead opportuni- providing by potential this unleashing is research in genomics cutting-edge and proteomics. for Genome Canadapotential untapped Canada’s to speaks panels review peer international by reviewed of Letters of Intent. The number of excellent projects the development of a simple blood test to to test heart condition; ahereditary identify blood simple a of development the implemented in2009–10. - - 5 4 • of its National GE National its of In 2009–10, Genome Canada will commence implementation Leadership totheNextLevel” also continue to nurture existing relationships to ensure maximum collaboration in the completion of approved projects. will Canada Genome partnerships. funding and scientific for opportunities and projects, special as or ICIs its through either funding, for requests into evolve may which opportunities, emerging out seek to continue will Canada Genome GE “Taking for Strategy National • • Canada in2009–10,Genomewillworktoward: Genome to funding future on Dependent level. next the to • bridging the gap between GE and makingitmeaningful; provide relevant GE relevant provide that vehicles outreach public effective encouraging development basedonresearchevidence; issues ofrelevant national interest, with and informing public aligned policy priorities research guiding at aimed initiatives various through policy public GE public and actively engage their views and interest on GE effective performance indicators develop for measuring and to evaluating process expert an initiating integration of GE the strengthen to initiatives continued encouraging 3 3 LS issues, and enhances visibility of GE LS success; Canadian public. the to genomics of successes and rewards risks, relative the of communication legal, social and other issues related to genomics research (GE research genomics to related issues other and social economic, environmental, legal, ethical, of area the in leadership of assumption The Objective 4: The encouragement of investment by other in the field of genomics genomics of field the in research. other by investment of encouragement The Objective 5: 3 LS Strategy for taking GE taking for Strategy LS 3 LS in large-scale genomics projects 3 LS information to the general general the to information LS 3 LS research and federal 3 LS leadership LS 3 LS research; 3 LS LS

communications to implemented in2009–10. the informing federal and public the Canada to Genome funding of research benefits the Communicating • • Education andPublicOutreach be conceptualizing, planning and organizing a GE international organizing signature and planning conceptualizing, take stock of 10 years’ worth of GE of worth years’ 10 of stock take enabling a vibrant GE vibrant a enabling application; results and mobilize the next phase of uptake and and amongrelevantstakeholdersacrossCanada. disciplines relevant across community broader government SECTION 1V–Plansfor2009–10 pr i or i t

i es plan f about o r G its e will n o role 3 m LS network and sense of of sense and network LS e be and 3 Ca LS event in 2010 to to 2010 in event LS nad developed 3 r e LS), and the the and LS), sults will a . 3 LS research LS A revised A continue and

29 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 30 GENOME CANADA — Corporate Plan 2009–10 SECTION 1V ClosingCashBalance OpeningCashBalance Excess(deficiency)of PROGRAM ANDOPERATING DISBURSEMENTS InvestmentIncome GovernmentofCanada RECEIPTS Planned Revenues Subsequent and Years Expenditures and 2009–10 RECEIPTSANDDISBURSEMENTS2009–10 PLANNED budget forfiscalyear2009–10willbepresentedtotheGenomeCanadaBoardofDirectorsapprovalinMarch2009. 2009meetings.Theoperating is basedonstatementsofcashflowaspresentedtotheBoardDirectorsatitsDecember2008andFebruary estimateofthereceipts anddisbursementsfor2009-10subsequentfiscalyears.Theestimate The followingtableprovidesapreliminary * As at February 2009 * AsatFebruary Revenue overDisbursements Total Disbursements Co-Funding GenomeCentres(6) GenomeCanada Operating Expenditures Technology Development Cancer StemCellConsortium C. difficile EspanaCompetition Genome Canada-Genoma International BarcodeofLife International RegulomeConsortium Public Population Project inGenomics Structural GenomicsConsortium Bovine GenomeSequencingProject Applied GenomicsinBioproductsandCrops Applied GenomicsInHumanHealthCompetition Competition III Competition II Competition I S&T Platforms Research Projects

– DETAILS Plansfor2009–10 (in millionsofdollars)* CUMULATIVE 720.6 673.0 to FORECAST 487.1 104.1 636.2 150.6 146.2 2008-09 2000-01 47.6 47.6 81.8 84.4 80.6 46.9 59.9 22.6 57.2 6.0 6.6 0.2 4.3 2.3 7.7 0.1

(17.7) 102.0 PLANNED 29.9 76.9 47.6 84.3 10.8 14.3 46.5 82.9 09-10 8.8 4.6 5.0 5.6 2.0 2.0 9.5 5.5 1.4 1.7

to 2010-2011 PLANNED (26.8) 149.2 2012-13 122.4 120.9 88.4 29.9 41.0 19.8 23.0 27.0 10.0 14.0 46.1 4.6 4.7 3.1 1.5

CUMULATIVE 924.2 PLANNED 652.4 927.3 to 159.4 840.0 2000-01 112.4 146.2 2012-13 207.1 80.6 66.4 59.9 93.0 55.6 87.3 32.3 15.8 * 25.0 4.0 6.0 9.9 0.2 7.7 3.1 3.1 2.1

1,028.0 1,028.0 CO-FUNDING to ESTIMATED 1,028.0 2000-01 2012-13 927.5 208.6 FROM 140.5 47.0 175.3 53.5 60.0 63.4 55.5 57.0 53.5 73.6 73.7 0.4 0.2 2.0 7.8 9.5

1,579.9 1,952.2 1,955.3 FUNDING GENOME CANADA 1,028.0 TOTAL & 159.9 212.9 840.0 CO- 207.6 286.7 154.3 415.7 133.5 119.9 112.6 85.0 69.4 93.0 87.3 15.5 71.3 19.4 0.4 4.4 4.1

100.0% 100.0% 80.9% 10.9% 8.2% 43.0% 52.6% 10.6% 14.7% 21.3% % 0.0% 0.8% 4.8% 4.4% 6.8% 5.8% 4.5% 0.2% 0.2% 3.6% 7.9% 3.7% 1.0% 6.1%

NEW ONGOING COMPLETED ONGOING DEVELOPMENT UNDER ONGOING COMPLETED OPERATING EXPENDITURES SCIENCE &TECHNOLOGY PLATFORMS STRATEGIC RESEARCHPRIORITIES Projects strategic priorities that have the potential for national and global scientific and socio-economic impact strategic prioritiesthathavethepotentialfornationalandglobalscientific andsocio-economic Research initiativesandactivitiesthatarecurrentlyunderdevelopment havebeenidentifiedbyGenomeCanadaassignificant Research initiativesandactivitiescurrentlysupportedbyGenomeCanada Status GENOME CANADAEXECUTIVESUMMARY • Polar • Genome • Genome • Education • Science • Competition • Technology • Competition • Applied • Turning DataintoKnowledgeWorkshop New GenomicsF Child HealthGenomicsCompetition Genomics Competition Aquatic &T Meeting Research inBioproductsorCrops Health Competition Genomics & Genomics Centres Canada National Technology and errestrial Animal Development in III Public Applied Workshop rontiers Competition Operations Operations Research Platform Outreach Genomics Competition in Human Leaders

• Data • • International • 3 • Protein • International • Cancer • International • Public • Structural • Aquaculture Competition Projects inHumanHealth,Plantsand Genome Canada/GenomaEspañaJoint Canada- Canada-Italy P International RegulomeConsortium(IRC) International BarcodeofLife(iBOL) International CancerGenomicsConsortium(ICGC) 4 rd th GenomeCanadaInternationalConference InternationalGenomicsConference Release Population Stem Ligand Chile Partnership Genomics International Cell Workshop Funders GE Knockout artnership Workshop 3 Consortium LS Symposium Project Consortium Forum Mouse in Genomics (CSCC) Consortium (SGC) (P

3 G) GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 3 2 GENOME CANADA — Corporate Plan 2009–10 EXECUTIVE SUMMARY Changing Landscape; recruitment of a Chief GE Chief a of recruitment Landscape; Changing of an international GE international an of organization initiatives: following the with framework research) genomics with associated issues social and legal refine its national GE and advance to continued Canada Genome 2008–09, In the meetingofeachproject’sobjectives. monitoring is in place to ensure continued progress towards of these interim reviews were successfully resolved. Ongoing each for committees review international the by identified issues remaining all 2008–09, In platforms. Technology and Science Canada-funded Genome six of review interim of 33 projects funded through Competition III, as well as an significant by co-funding undertaking of an interim review management, selection and support of excellent science, and application of rigorous principles and standards for project its demonstrated Canada Genome 2007–08, During to anend. came ligands protein to related project the in involvement proteomics research collaborations and consortiums. It consortiums. and collaborations research proteomics and genomics international important in participation continued with leadership international its strengthen will Canada Genome importance.international and national of research scientific for opportunities rich the on capitalize and research proteomics and genomics of edge cutting the at presence its sustain to desire its reflect 2009–10 for initiatives ongoing and proposed Canada’s Genome research totheCanadianpublicandkeystakeholders. proteomics and genomics of successes and rewards risks, the communicated Canada Genome ways many the among were exhibition travelling Genome In GEEE! the support to Nature of Museum Canadian the with partnership and programs, education youth and conferences science key of Press conferences, a new web site, press releases, sponsorship international leadershipintheareaofGE and national assuming for strategy a of development and 3 LS (ethical, environmental, economic, 3 LS symposium—Navigating the symposium—Navigating LS 3 LS. 3 LS Officer,LS that GenomeCanadahascometorepresent. proteomics and genomics in creativity and innovation the from benefit to continue Canadians and Canada the research momentum it has created and ensure that funding will enable Genome Canada to keep pace with edge in these fields. Additional and appropriate federal knowl- and development discovery, for force national a become has Canada Genome Canada, in research proteomics and genomics for resource information and funding primary the as establishment its Since Canada tofulfilitsfiveobjectives. Genome for corrections” “course necessary any make to order in assessment evaluation the review will and, effectiveness; economy,cost of and terms efficiency in Canada’s operations and programs are “best-in-class” Genome ensure to order in suggestions and practices best for audit performance five-year the of results the mine will It research. genomics in developments new changing rapidly technology,and platform genomics, polar release, data to respect with knowledge latest the gain to researchers genomics international and will facilitate workshops and conferences for Canadian Each oftheelementsandtheirunderlyingcomponentsisdisplayedinfigurebelow. SECTION V • EvaluationFramework • AuditFramework • Performance MonitoringandMeasurementFramework The threekeyelementsare: The PAES comprisesthreekeyelementsandtwosupportingelements, eachofwhichareintegraltothestrategy. these functionsismaintained.ImplementationoftheStrategybeganin2008-09. specific requirements of the latest funding agreement Canada, with and Industry to ensure that a comprehensive and integrated approach to and evaluation. In 2007–08, the Board of Genome Canada approved a new Performance, Audit and Evaluation Strategy (PAES) to respond to Genome Canada has a wide array of policies, systems and processes that have been developed over time to address issues of performance, audit ** The term“Project” meansbothResearchProjects andScienceTechnology Platforms. • Final • Performance • Interim • Project • Project PERFORMANCE MONITORING Project • RiskManagementFrameworkOperationsand •GovernanceRegime

Selection Review Monitoring – •CorporatePlanAnnualReportWebSiteSpecialPublications Performance, AuditandEvaluation Strategy Reports Indicators ** PERFORMANCE REPORTING RISK MANAGEMENT • Performance • Compliance • Recipient • Financial AUDITS • • The twosupportingelementsare: Audits Audits Risk Management Performance Reporting Audits Audits • Evaluations • Logic • Results-based and Accountability Framework (RMAF) EVALUATION Model every Management five years

31 GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 32 GENOME CANADA — Corporate Plan 2009–10 SECTION V izing anationalsystemforcapturingperformanceinformationfromacrossallprojectsinconsolidatedmanner. In fiscal year 2009–10, Genome Canada will concentrate on completing the process for assessing final project reports, and on final Directors inMarch2009. of Board the to submission for planned are undertakings significant two these on reports Final undertaken. were Canada Industry with agreement funding the in PAESand the in both for called were that evaluation the and audit performance the of completion ensuring to related activities 2008–09, (www.genomecanada.ca).In website Canada’s Genome on full in viewed be can PAESThe FINANCIAL AUDITS ANDANNUAL REPORTS 2002-03 (Quebec City) Genome Canada Retreat –

Performance, AuditandEvaluationStrategy 2003-04 EVALUATION (RMAF) 2004-05 (Winnipeg) Genome Canada Retreat

C 2005-06 OMPLIANCE A UDIT 2006-07 (Ottawa) Genome Canada Retreat AUDIT AND STRATEGY EVALUATION

2007-08 2008-09 AUDIT PERFORMANCE

EVALUATION - EXECUTIVE SUMMARY the final reports will be developed in 2009–10 as part as 2009–10 in developed be will reports final the Aquaculture, were received. The process for the review of Genome España in the areas of Human Health, Plants and with competition international bilateral first Canada’s Genome and Health, Human in ProteomicsResearch and Genomics Applied competition, strategic first Canada’s Genome of reports final the 2008–09, year fiscal In practices indeliveringhighqualitytechnologyservices. and methods best as well as technologies, in advances of details share and meet to platforms other of leaders and platforms, Canada-funded Genome six the of leaders the which took place in January 2009 was an opportunity for meeting Leaders Platform Technology and Science The community. scientific Canadian entire the to available technologies of menu the update and widen will results These 2010. in results produce will Competition opment Technologythe of aegis the under funded projects Devel research innovative thirteen The researchers. proteomics and genomics Canadian for available is technology edge cutting- that ensuring to committed is Canada Genome funding support. merit which areas as PositionPaperProcess the of cycle second the in identified agriculture-animals—were and health themes—child research strategic more two 2008, of fall the In support. funding merit which areas as cycle Paper Position first the in recommended been had themes research two These bioproducts. and plants agriculture– of themes research strategic the address to competition a launched Canada Genome 2008–09, In role in the overall strategic activities of Genome Canada. pivotal a play to continued Canadians) to importance socio-economic of and interest of areas recognized funding to targeted strategic research themes in nationally allocating for approach (an Process Paper Position The national and global scientific and socio-economic impact,andreceiptbyGenomeCanadaofnewfundingsupport. national andglobalscientificsocio-economic outcomes of international peer reviews, assessments of scientific merit and relevance, assessments of the potential for any new large-scale research activities in 2009–10 will be contingent upon a number of factors, including the successful the fiscal framework of funding allocated to Genome Canada for the achievement of its five objectives, the initiation of within fall activities proposed the While 2009–10. year fiscal for results expected and activities planned the outlines Genome Canada’s Corporate Plan 2009–10 summarizes the activities and results achieved in fiscal year 2008–09 and -

and the economy. Also in 2008–09, Genome Canada's Genome 2008–09, in Also economy. the and scientific advances and their potential impact on society latest the hear to industry and media the government, academia, in policy-makers and decision- researchers, for platform exciting an Society—offered on Science of Impact The Vision: conference—2020 international third Canada’s Genome industry). aquaculture the to related projects research genomics large-scale of collaboration on (focused partnership Canada–Chile the and health), human to related projects research genomics large-scale of collaboration on (focused partnership Canada–Italy the Consortium, Genome Cancer International the Life, of Barcode International the Consortium, Regulome International the as such opportunities future in involvement as well as Forum, organization of the second annual International Funders’ the included initiatives Other scientists. Canadian and Canada of status international the enhances and Consortium—strengthens Cell Stem Cancer the and Genomics, the International Knockout Mouse Consortium, in PopulationProjectPublic the Consortium, Genomics Structural initiatives—the consortium international Genome Canada’s ongoing support and interest in several research projects, workshops, consortia and partnerships. international select in leadership of assumption and targeted in 2008–09. The strategy involved engagement specifically was research proteomics and genomics of arena international the in presence Canada’s Genome these projects. offered, including the potential applications arising from benefits socio-economic the also but objectives, project the to relative accomplishments the determine only not will, projects these of assessment comprehensive A activities. Strategy Evaluation and Audit Performance, Canada’s Genome of implementation on-going the of GENOME CANADA — Corporate Plan 2009–10 Plan Corporate — CANADA GENOME 1 Published by Genome Canada ACKNOWLEDGEMENT Extracts from this document may be reproduced for individual use without permission provided the Government of Canada source is fully acknowledged. However, reproduction in whole or in part for purposes of resale or redistribution requires prior written permission from Genome Canada. Genome Canada would like to thank the Government of Canada for its support. © Genome Canada 2009 150 Metcalfe Street, Suite 2100 Ottawa, Ontario K2P 1P1 Telephone: (613) 751-4460 Facsimile: (613) 751-4474 Email: [email protected] Website: www.genomecanada.ca